Freetown
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			-		with Standardized inclue				050/ 01
DI 11 111	<u>Obs</u>	<u>Ехр</u>	SIR	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar					Melanoma of Skin				
Male	9	7.6	117.9	(53.8-223.9)	Male	3	4.7	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	5	3.8	133.1	(42.9-310.7)
Brain and Othe	r Nervo	us Systen	<u>n</u>		Multiple Myeloma				
Male	0	1.7	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	0	0.3	nc	(nc-nc)	Male	5	4.4	114.4	(36.9-267.0)
Female	28	31.9	87.8	(58.3-126.8)	Female	2	3.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>			
					Male	3	3.5	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Colon / Rectum	<u>1</u>				<u>Ovary</u>				
Male	13	12.0	108.1	(57.5-184.8)					
Female	6	9.9	60.5	(22.1-131.7)	Female	3	3.3	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Hodgkin Lympl	noma				<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	36	33.7	106.8	(74.8-147.8)
Female	0	0.6	nc	(nc-nc)					(
Kidney & Rena	l Pelvis			, ,	Stomach				
Male	2	3.6	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Larynx</u>				, ,	<u>Testis</u>				, ,
Male	2	1.5	nc	(nc-nc)	 Male	2	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)					(/
<u>Leukemia</u>				(/	<u>Thyroid</u>				
Male	3	2.6	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
Liver and Intral				(**************************************	Uteri Corpus and L				(,
Male	1	1.7	nc nc	(nc-nc)	<u> </u>	210.007.11	<u></u>		
Female	0	0.5	nc	(nc-nc)	Female	4	6.4	nc	(nc-nc)
Lung and Bron		***		(/	All Sites / Types	•			()
Male	18	15.1	119.4	(70.7-188.7)	Male	111	110.4	100.5	(82.7-121.0)
Female	9	12.5	72.2	(33.0-137.1)	Female	77	97.7	78.8	(62.2-98.5)
i Citiaic	,	14.0	1 4.4	(33.0 137.1)	i Ciliaic	11	71.1	70.0	(02.2-70.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gardner
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•	95% CI	With Standardized inclue		_	SIR	95% CI
Bladder, Urinar	Obs	<u>Exp</u>	<u>SIR</u>	93% CI	Melanoma of Skin	<u>Obs</u>	<u>Exp</u>	SIK	93% CI
Male	y 27	24.9	108.6	(71.6-158.0)	Male	5	13.0	38.4	(12.4-89.6)
Female	7	9.0	78.1	(31.3-161.0)	Female	2	9.8	nc	(nc-nc)
Brain and Othe				(31.3 101.0)	Multiple Myeloma	2	7.0	TIC	(no no)
Male	4	4.6	nc	(nc-nc)	Male	0	3.6	nc	(nc-nc)
Female	2	3.8	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>	2	5.0	TIC	(110-110)	Non-Hodgkin Lym		2.7	TIC	(110-110)
Male	3	0.8	nc	(nc-nc)	Male	10	12.6	79.4	(38.0-146.1)
Female	85	84.0	101.2	(80.9-125.2)	Female	7	11.3	61.9	(24.8-127.6)
Cervix Uteri				(**** *=**=/	Oral Cavity & Pha				(=,
					Male	8	8.8	90.6	(39.0-178.5)
Female	2	3.6	nc	(nc-nc)	Female	6	4.4	137.2	(50.1-298.7)
Colon / Rectum	l			, ,	<u>Ovary</u>				, ,
Male	31	37.3	83.1	(56.4-117.9)					
Female	30	37.4	80.2	(54.1-114.5)	Female	14	9.1	154.3	(84.3-258.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	6.0	nc	(nc-nc)	Male	7	7.0	99.9	(40.0-205.7)
Female	2	1.8	nc	(nc-nc)	Female	10	7.9	126.1	(60.3-231.8)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	1	2.0	nc	(nc-nc)	Male	86	94.8	90.8	(72.6-112.1)
Female	0	1.5	nc	(nc-nc)					
Kidney & Renal	<u>Pelvis</u>				<u>Stomach</u>				
Male	10	9.8	101.8	(48.7-187.2)	Male	2	6.3	nc	(nc-nc)
Female	3	6.2	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	6	4.1	146.2	(53.4-318.3)	Male	1	3.7	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	8	7.7	103.8	(44.7-204.6)	Male	2	2.6	nc	(nc-nc)
Female	4	6.4	nc	(nc-nc)	Female	8	7.3	108.8	(46.9-214.5)
Liver and Intrah	<u>nepatic I</u>	Bile Duct	<u>s</u>		Uteri Corpus and	<u>Uterus, N</u>	<u>OS</u>		
Male	2	4.6	nc	(nc-nc)					
Female	1	1.8	nc	(nc-nc)	Female	18	16.8	107.1	(63.4-169.2)
Lung and Bron					All Sites / Types				
Male	49	46.3	105.9	(78.3-140.0)	Male	290	322.6	89.9	(79.9-100.9)
Female	40	41.2	97.1	(69.4-132.2)	Female	267	294.3	90.7	(80.2-102.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

GeorgetownObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		vith Standardized Inciden				0=0/.0:
D	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary				(05.0.40.4.)	Melanoma of Skin	_			(= 000.0)
Male -	5	6.3	79.9	(25.8-186.6)	Male	5	3.9	128.7	(41.5-300.3)
Female	1	2.1	nc	(nc-nc)	Female	6	3.2	188.9	(69.0-411.2)
Brain and Other		-	<u>n</u>		Multiple Myeloma				
Male	2	1.5	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lympl	<u>noma</u>			
Male	0	0.2	nc	(nc-nc)	Male	8	3.6	222.9	(96.0-439.2)
Female	28	26.7	105.0	(69.8-151.8)	Female	5	3.0	167.7	(54.0-391.3)
Cervix Uteri					Oral Cavity & Phary	<u>nx</u>			
					Male	2	2.9	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	12	9.8	121.9	(62.9-212.9)					
Female	12	8.7	138.3	(71.4-241.6)	Female	3	2.7	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	4	1.7	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Hodgkin Lymph	<u>ioma</u>				<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	24	27.2	88.2	(56.5-131.3)
Female	0	0.5	nc	(nc-nc)					
Kidney & Renal	Pelvis				<u>Stomach</u>				
Male	1	3.0	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.2	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	2.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
Liver and Intrah	epatic E	Bile Ducts	<u>S</u>		Uteri Corpus and Ut	erus, NOS	<u>.</u>		
Male	0	1.4	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
Lung and Brond	:hus				All Sites / Types				
Male	19	12.3	154.3	(92.8-241.0)	Male	104	90.1	115.4	(94.3-139.9)
Female	10	10.6	94.7	(45.3-174.2)	Female	84	83.0	101.2	(80.7-125.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gill
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•	· ·	th Standardized Incidence	-			050/ 01
Dladdar Hrimanı	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>	Malanama of Chin	<u>Obs</u>	<u>Ехр</u>	SIR	<u>95% CI</u>
Bladder, Urinary	2	1 -		()	Melanoma of Skin	1	0.0		(
Male	2	1.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Brain and Other N				, ,	Multiple Myeloma				, ,
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymph	<u>noma</u>			
Male	0	0.0	nc	(nc-nc)	Male	2	8.0	nc	(nc-nc)
Female	5	6.0	83.7	(27.0-195.4)	Female	2	0.7	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharyr	<u>1X</u>			
					Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	2	2.4	nc	(nc-nc)					
Female	2	2.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Hodgkin Lympho	<u>ma</u>				<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	6.1	82.3	(26.5-192.0)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal P	<u>elvis</u>				<u>Stomach</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Liver and Intraher	oatic Bile	e Ducts			Uteri Corpus and Ute	erus, NOS			
Male	0	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Lung and Bronch	<u>us</u>				All Sites / Types				
Male	1	2.9	nc	(nc-nc)	Male	17	20.7	82.2	(47.8-131.6)
Female	4	2.5	nc	(nc-nc)	Female	18	19.0	94.9	(56.2-150.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			-		with Standardized inclu				050/ 01
BI II II:	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urina				(7.1.0.1.10.0)	Melanoma of Skin				(aa.
Male	36	35.4	101.8	(71.3-140.9)	Male	15	19.0	79.1	(44.2-130.4)
Female	15	13.4	112.1	(62.7-184.9)	Female	14	15.7	89.3	(48.8-149.8)
Brain and Oth	er Nervo	ous Syster	<u>n</u>		Multiple Myeloma				
Male	5	6.6	76.2	(24.6-177.9)	Male	4	5.2	nc	(nc-nc)
Female	8	5.9	135.0	(58.1-266.0)	Female	7	4.4	160.0	(64.1-329.6)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	1	1.1	nc	(nc-nc)	Male	21	18.1	116.2	(71.9-177.6)
Female	128	137.1	93.4	(77.9-111.0)	Female	15	17.2	87.1	(48.7-143.7)
Cervix Uteri					Oral Cavity & Pha	rynx			
					Male	22	13.6	162.1	(101.5-245.4)
Female	6	5.9	102.0	(37.2-222.0)	Female	5	6.9	72.6	(23.4-169.5)
Colon / Rectur	<u>m</u>				<u>Ovary</u>				
Male	48	53.7	89.4	(65.9-118.5)					
Female	70	55.0	127.3	(99.2-160.9)	Female	11	14.5	75.8	(37.8-135.6)
Esophagus					<u>Pancreas</u>				
Male	9	8.9	101.4	(46.3-192.4)	Male	19	10.2	187.0	(112.5-292.1)
Female	1	2.6	nc	(nc-nc)	Female	12	11.6	103.1	(53.2-180.1)
Hodgkin Lymp	homa				<u>Prostate</u>				
Male	3	2.7	nc	(nc-nc)	Male	139	145.1	95.8	(80.6-113.1)
Female	5	2.3	216.6	(69.8-505.4)					
Kidney & Rena	al Pelvis	<u> </u>			<u>Stomach</u>				
Male	14	14.7	95.1	(51.9-159.5)	Male	8	9.0	88.88	(38.2-174.9)
Female	12	9.7	123.3	(63.6-215.4)	Female	7	5.8	120.7	(48.3-248.6)
<u>Larynx</u>					<u>Testis</u>				
Male	9	6.2	144.6	(66.0-274.4)	Male	7	4.6	150.7	(60.4-310.6)
Female	2	1.8	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	16	10.9	146.7	(83.8-238.2)	Male	5	3.8	132.9	(42.8-310.1)
Female	8	9.5	83.9	(36.1-165.3)	Female	15	12.2	123.1	(68.8-203.0)
Liver and Intra	hepatic	Bile Duct	S		Uteri Corpus and	Uterus, N	IOS		
Male	9	6.9	130.3	(59.5-247.4)					
Female	2	2.7	nc	(nc-nc)	Female	24	27.9	86.0	(55.1-128.0)
Lung and Broi				•	All Sites / Types				,
Male	72	67.8	106.3	(83.1-133.8)	Male	508	474.6	107.0	(97.9-116.8)
Female	69	63.6	108.4	(84.3-137.2)	Female	468		101.7	(92.7-111.4)
				/					, ,

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003 95% CI Obs **Exp** SIR <u>Obs</u> <u>Exp</u> <u>SIR</u> 95% CI Bladder, Urinary Melanoma of Skin Male 0 1.0 (nc-nc) Male 0 0.6 nc (nc-nc) nc 0 Female 0.3 nc (nc-nc) Female 0 0.5 (nc-nc) nc Brain and Other Nervous System Multiple Myeloma Male 0 Male 0 0.2 0.2 nc (nc-nc) nc (nc-nc) 0 0.2 Female 0 0.1 Female nc (nc-nc) nc (nc-nc) **Breast** Non-Hodgkin Lymphoma 0 0 0.5 Male 0.0 (nc-nc) Male nc (nc-nc) nc Female 1 3.9 (nc-nc) Female 0 0.4 (nc-nc) nc nc Cervix Uteri Oral Cavity & Pharynx Male 1 0.4 (nc-nc) nc 0 Female 0 0.2 Female 0.2 (nc-nc) nc (nc-nc) nc Colon / Rectum Ovary Male 0 1.6 (nc-nc) nc Female 0 1.3 nc (nc-nc) Female 0 0.4 nc (nc-nc) **Pancreas Esophagus** 0 Male 1 0.3 nc (nc-nc) Male 0.3 nc (nc-nc) Female 0 0.1 nc (nc-nc) Female 0 0.3 nc (nc-nc) Hodgkin Lymphoma **Prostate** Male 0 0.1 Male 135.7 (49.5-295.3) (nc-nc) 6 4.4 nc 0 Female 0.1 (nc-nc) nc Kidney & Renal Pelvis **Stomach** 0 Male 2 0.5 Male 0.3 (nc-nc) nc (nc-nc) nc Female 0 Female 0 0.1 0.3 nc (nc-nc) nc (nc-nc) <u>Larynx</u> <u>Testis</u> 0 Male 0 0.2 0.1 nc (nc-nc) Male nc (nc-nc) Female 0 0.0 nc (nc-nc) **Leukemia Thyroid** 0 1 0.1 Male 0.3 (nc-nc) Male nc (nc-nc) nc Female 0 0.2 Female 1 0.4 (nc-nc) (nc-nc) nc nc Uteri Corpus and Uterus, NOS Liver and Intrahepatic Bile Ducts Male 0 0.2 (nc-nc) nc Female 0 0.1 1 8.0 nc (nc-nc) Female nc (nc-nc) Lung and Bronchus All Sites / Types Male 0 2.0 Male 12 84.0 (43.3-146.7) (nc-nc) 14.3 nc 2 (18.1-107.9)Female 1.5 nc (nc-nc) Female 6 12.1 49.6

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

GosnoldObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

		•			ith Standardized Incidence Ra				
	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Brain and Other Ne	rvous Sys	<u>tem</u>			Multiple Myeloma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymphon	<u>na</u>			
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	0	0.2	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Hodgkin Lymphom	<u>a</u>				<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
Kidney & Renal Pel	<u>vis</u>				<u>Stomach</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Liver and Intrahepa	tic Bile Du	<u>icts</u>			Uteri Corpus and Uteru	s, NOS			
Male	0	0.0	nc	(nc-nc)					
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Lung and Bronchus	<u>s</u>				All Sites / Types				
Male	0	0.3	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

GraftonObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		ith Standardized Inciden			3 <u>SIR</u>	<u>95% CI</u>
Bladder, Urinar	Obs	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	Melanoma of Skin	<u>Obs</u>	<u>Exp</u>	SIK	73 /0 CI
Male	<u>.</u> 11	13.7	80.1	(40.0-143.4)	Male	7	7.9	89.1	(35.7-183.6)
Female	7	4.9	142.5	(57.1-293.6)	Female	4	6.7	nc	(nc-nc)
Brain and Othe				(07.1 275.0)	Multiple Myeloma		0.7	110	(no no)
Male	0	2.9	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>	Ü	2.0	110	(10 110)	Non-Hodgkin Lym		1.0	110	(110 110)
Male	1	0.4	nc	(nc-nc)	Male	7	7.4	94.0	(37.6-193.6)
Female	75	55.3	135.5	(106.6-169.9)	Female	7	6.7	104.6	(41.9-215.6)
Cervix Uteri				(Oral Cavity & Phar				(
					Male	3	5.5	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
Colon / Rectum	<u>1</u>				<u>Ovary</u>				
Male	18	21.1	85.5	(50.6-135.1)					
Female	20	20.1	99.6	(60.8-153.8)	Female	5	5.8	86.3	(27.8-201.4)
Esophagus					<u>Pancreas</u>				
Male	2	3.5	nc	(nc-nc)	Male	6	4.0	150.8	(55.1-328.3)
Female	2	1.0	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<u>Hodgkin Lympl</u>	<u>homa</u>				<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	41	56.0	73.2	(52.5-99.3)
Female	0	1.1	nc	(nc-nc)					
Kidney & Rena	<u>l Pelvis</u>				<u>Stomach</u>				
Male	6	5.9	100.9	(36.8-219.5)	Male	3	3.5	nc	(nc-nc)
Female	5	3.8	131.5	(42.4-306.8)	Female	3	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	2.5	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	4	4.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	3.8	nc	(nc-nc)	Female	5	5.8	86.6	(27.9-202.0)
Liver and Intral	•			, ,	Uteri Corpus and L	Jterus, N	<u>0S</u>		
Male	2	2.8	nc	(nc-nc)		4.	44.4	405.0	((0.0.044.0)
Female	0	1.0	nc	(nc-nc)	Female	14	11.1	125.9	(68.8-211.2)
Lung and Bron		2/ 4	047	(/101007)	All Sites / Types	151	100.4	00.3	(/0.0.04.1)
Male	25	26.4	94.6	(61.2-139.7)	Male	151	188.1	80.3	(68.0-94.1)
Female	23	24.1	95.4	(60.5-143.2)	Female	187	180.6	103.6	(89.2-119.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granby
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

<u>Obs</u> <u>Exp</u> SIR 95% CI <u>Obs</u> **Exp** <u>SIR</u> 95% CI Bladder, Urinary Melanoma of Skin Male 6 6.1 97.6 (35.6-212.4)Male 2 3.5 nc (nc-nc) 0 Female 2.0 nc (nc-nc) Female 2 2.8 (nc-nc) nc **Brain and Other Nervous System** Multiple Myeloma Male 0.9 Male 1 1.3 nc (nc-nc) 0 nc (nc-nc) 1 1.0 1 Female nc (nc-nc) Female 0.7 nc (nc-nc) Non-Hodgkin Lymphoma **Breast** 2 Male 0.2 nc (nc-nc) Male 3.3 nc (nc-nc) Female 23 23.5 97.8 (62.0-146.7)Female 0 2.7 (nc-nc) nc Cervix Uteri Oral Cavity & Pharynx Male 5 2.5 196.4 (63.3-458.3)0 1.1 Female 1 1.1 nc (nc-nc) Female nc (nc-nc) Colon / Rectum Ovary Male 9.5 8 84.5 (36.4-166.5)Female 8 8.0 99.8 (43.0-196.7)Female 0 2.4 nc (nc-nc) **Pancreas Esophagus** 2 Male 0 1.6 nc (nc-nc) Male 1.8 nc (nc-nc) Female 0 0.4 nc (nc-nc) Female 1 1.7 nc (nc-nc) Hodgkin Lymphoma **Prostate** Male 0 0.5 nc Male 21 80.1 (49.5-122.4)(nc-nc) 26.2 Female 0 0.4 (nc-nc) nc Kidney & Renal Pelvis Stomach Male 4 2.7 Male 1 1.6 (nc-nc) nc (nc-nc) nc Female 0 1.6 Female 0 8.0 nc (nc-nc) nc (nc-nc) **Larynx Testis** 2 Male 1.1 nc (nc-nc) Male 1 1.0 nc (nc-nc) Female 0 0.3 nc (nc-nc) Leukemia **Thyroid** 2 2 Male 2.0 nc (nc-nc) Male 0.7 nc (nc-nc) Female 1 Female 2 2.4 1.5 nc (nc-nc) nc (nc-nc) **Liver and Intrahepatic Bile Ducts** Uteri Corpus and Uterus, NOS Male 0 1.3 (nc-nc) nc 0 104.9 Female 0.4 nc (nc-nc) Female 5 4.8 (33.8-244.8)Lung and Bronchus All Sites / Types Male (63.5-195.1) Male 78 85.5 91.2 (72.1-113.8)14 12.0 116.3 78.8 Female 11 10.0 110.0 (54.8-196.8)Female 59 74.9 (60.0-101.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granville
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		ith Standardized Incident				0=0/ 0:
51 11 111	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar				, ,	Melanoma of Skin				, ,
Male	1	1.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Brain and Other	r Nervou	is Systen	<u>n</u>		Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymph	<u>noma</u>			
Male	0	0.0	nc	(nc-nc)	Male	1	8.0	nc	(nc-nc)
Female	6	5.7	104.7	(38.2-228.0)	Female	1	0.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary	<u>1X</u>			
					Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Colon / Rectum	<u> </u>				<u>Ovary</u>				
Male	1	2.2	nc	(nc-nc)					
Female	2	1.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	6.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal	<u>Pelvis</u>				<u>Stomach</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Liver and Intrah	nepatic B	Bile Ducts	<u> </u>		Uteri Corpus and Ut	erus, NOS	1		
Male	0	0.3	nc	(nc-nc)	·				
Female	0	0.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Lung and Brone	<u>chus</u>				All Sites / Types				
Male	3	2.9	nc	(nc-nc)	Male	16	20.6	77.8	(44.4-126.3)
Female	2	2.4	nc	(nc-nc)	Female	18	17.9	100.7	(59.7-159.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Great Barrington
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Ехр</u>	SIR	95% CI	With Standardized inclue	Obs	<u>Exp</u>	SIR	95% CI
Bladder, Urinar	У				Melanoma of Skin				
Male	8	9.9	80.7	(34.7-159.0)	Male	7	5.0	141.1	(56.5-290.7)
Female	3	4.0	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
Brain and Other	r Nervou	ıs Systen	<u>n</u>		Multiple Myeloma				
Male	1	1.7	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	1	0.3	nc	(nc-nc)	Male	6	4.8	124.0	(45.3-269.9)
Female	26	37.9	68.6	(44.8-100.5)	Female	2	5.1	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>			
					Male	4	3.5	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
Colon / Rectum	-				<u>Ovary</u>				
Male	13	14.9	87.3	(46.4-149.3)					
Female	16	17.2	93.2	(53.2-151.3)	Female	4	4.1	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	2	2.4	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	46	37.6	122.4	(89.6-163.3)
Female	0	0.6	nc	(nc-nc)					
Kidney & Renal	<u>Pelvis</u>				<u>Stomach</u>				
Male	3	3.8	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	2.9	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
Liver and Intrah	•		<u>S</u>		Uteri Corpus and L	<u>Jterus, NC</u>	<u>)S</u>		
Male	2	1.8	nc	(nc-nc)					
Female	0	0.8	nc	(nc-nc)	Female	7	7.7	91.3	(36.6-188.0)
Lung and Brond					All Sites / Types				
Male .	19	18.3	104.1	(62.6-162.5)	Male	127	126.6	100.3	(83.6-119.3)
Female	17	18.4	92.4	(53.8-147.9)	Female	110	132.3	83.2	(68.3-100.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

GreenfieldObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

Bladder, Urinary SIR 95% CI Obs Exp SIR 95% CI Male 19 22.0 86.4 (52.0-135.0) Male 6 11.2 53.6 (19.6-116.7) Female 15 9.2 163.2 (91.3-269.2) Female 7 9.7 72.2 (28.9-148.7) Brain and Other Nervews System Multiple Myeloma Male 3 3.8 nc (nc-nc) Male 4 3.1 nc (nc-nc) Female 3 3.8 nc (nc-nc) Female 2 3.0 nc (nc-nc) Female 3 3.8 nc (nc-nc) Female 2 3.0 nc (nc-nc) Breast Non-Hodgkin Lymphoma Male 9 0.7 nc (nc-nc) Female 13 11.5 112.7 (60.0-192.8) Cervix Uteri Male 3 7.7 nc (nc-nc) <
Male 19 22.0 86.4 (52.0-135.0) Male 6 11.2 53.6 (19.6-116.7) Female 15 9.2 163.2 (91.3-269.2) Female 7 9.7 72.2 (28.9-148.7) Brain and Other Verveus System Multiple Myeloma Male 3 3.8 nc (nc-nc) Male 4 3.1 nc (nc-nc) Female 3 3.8 nc (nc-nc) Female 2 3.0 nc (nc-nc) Breast Non-Hodgkin Lymphoma Male 0 0.7 nc (nc-nc) Male 9 10.9 82.5 (37.6-156.6) Female 88 84.8 103.8 (83.2-127.9) Female 13 11.5 112.7 (60.0-192.8) Cervix Uteri Male 3 7.7 nc (nc-nc) Female 9 3.3 7.7 nc (nc-nc)
Female 15 9.2 163.2 (91.3-269.2) Female 7 9.7 72.2 (28.9-148.7) Brain and Other Verveus System Multiple Myeloma Male 3 3.8 nc (nc-nc) Male 4 3.1 nc (nc-nc) Female 3 3.8 nc (nc-nc) Female 2 3.0 nc (nc-nc) Breast Non-Hodgkin Lymphoma Male 0 0.7 nc (nc-nc) Male 9 10.9 82.5 (37.6-156.6) Female 88 84.8 103.8 (83.2-127.9) Female 13 11.5 112.7 (60.0-192.8) Cervix Uteri Drail Cavity & Pharum Female 9 3.5 257.1 (117.3-488.1) Female 3 7.7 nc (nc-nc) Female 9 3.5 257.1 (117.3-488.1) Female 2 4.4 nc (nc-nc)
Brain and Other Ververs System Multiple Myeloma Male 3 3.8 nc (nc-nc) Male 4 3.1 nc (nc-nc) Female 3 3.8 nc (nc-nc) Female 2 3.0 nc (nc-nc) Breast Non-Hodgkin Lymphoma Male 0 0.7 nc (nc-nc) Male 9 10.9 82.5 (37.6-156.6) Female 88 84.8 103.8 (83.2-127.9) Female 9 10.9 82.5 (37.6-156.6) Cervix Uteri Oral Cavity & Pharym Female 3 7.7 nc (nc-nc) Female 3 7.7 nc (nc-nc) Colon / Rectum 2 4.4 nc (nc-nc) Male 25 33.0 75.8 (49.1-112.0) Ovary 8 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Male 3 3.8 nc (nc-nc) Male 4 3.1 nc (nc-nc) Female 3 3.8 nc (nc-nc) Female 2 3.0 nc (nc-nc) Breast Non-Hodgkin Lymboma Male 0 0.7 nc (nc-nc) Male 9 10.9 82.5 (37.6-156.6) Female 88 84.8 103.8 (83.2-127.9) Female 13 11.5 112.7 (60.0-192.8) Cervix Uteri Male 3 7.7 nc (nc-nc) Female 9 3.5 257.1 (117.3-488.1) Female 2 4.4 nc (nc-nc) Colon / Rectum Ovary
Female 3 3.8 nc (nc-nc) Female 2 3.0 nc (nc-nc) Breast Non-Hodgkin Lymboma Male 0 0.7 nc (nc-nc) Male 9 10.9 82.5 (37.6-156.6) Female 88 84.8 103.8 (83.2-127.9) Female 13 11.5 112.7 (60.0-192.8) Cervix Uteri
Breast Non-Hodgkin Lymboma Male 0 0.7 nc (nc-nc) Male 9 10.9 82.5 (37.6-156.6) Female 88 84.8 103.8 (83.2-127.9) Female 13 11.5 112.7 (60.0-192.8) Cervix Uteri
Male 0 0.7 nc (nc-nc) Male 9 10.9 82.5 (37.6-156.6) Female 88 84.8 103.8 (83.2-127.9) Female 13 11.5 112.7 (60.0-192.8) Cervix Uteri Male 3 7.7 nc (nc-nc) Female 9 3.5 257.1 (117.3-488.1) Female 2 4.4 nc (nc-nc) Colon / Rectum 25 33.0 75.8 (49.1-112.0) Ovary Emale 9 10.9 82.5 (37.6-156.6) (60.0-192.8)
Female 88 84.8 103.8 (83.2-127.9) Female 13 11.5 112.7 (60.0-192.8) Cervix Uteri Oral Cavity & Pharymx Male 3 7.7 nc (nc-nc) Female 9 3.5 257.1 (117.3-488.1) Female 2 4.4 nc (nc-nc) Colon / Rectum 25 33.0 75.8 (49.1-112.0)
Cervix Uteri Oral Cavity & Pharynx Kernale 9 3.5 257.1 (117.3-488.1) Female 2 4.4 nc (nc-nc) Colon / Rectum Ovary Ovary V
Female 9 3.5 257.1 (117.3-488.1) Female 2 4.4 nc (nc-nc) Colon / Rectum Ovary Male 25 33.0 75.8 (49.1-112.0) 49.1-112.0
Female 9 3.5 257.1 (117.3-488.1) Female 2 4.4 nc (nc-nc) Colon / Rectum Ovary Male 25 33.0 75.8 (49.1-112.0)
Colon / Rectum Ovary Male 25 33.0 75.8 (49.1-112.0)
Male 25 33.0 75.8 (49.1-112.0)
Female 40 39.4 101.5 (72.5-138.3) Female 9 9.2 97.7 (44.6-185.5)
<u>Esophagus</u> <u>Pancreas</u>
Male 2 5.2 nc (nc-nc) Male 6 6.2 96.9 (35.4-211.0)
Female 1 1.8 nc (nc-nc) Female 8 8.3 96.7 (41.6-190.6)
Hodgkin Lymphoma Prostate
Male 0 1.6 nc (nc-nc) Male 67 81.3 82.4 (63.9-104.7)
Female 3 1.5 nc (nc-nc)
Kidney & Renal Pelvis Stomach
Male 6 8.5 70.6 (25.8-153.6) Male 6 5.6 107.3 (39.2-233.5)
Female 4 6.3 nc (nc-nc) Female 0 4.3 nc (nc-nc)
<u>Larynx</u> <u>Testis</u>
Male 2 3.6 nc (nc-nc) Male 4 2.7 nc (nc-nc)
Female 0 1.0 nc (nc-nc)
<u>Leukemia</u> <u>Thyroid</u>
Male 3 6.7 nc (nc-nc) Male 0 2.1 nc (nc-nc)
Female 5 6.5 76.4 (24.6-178.2) Female 4 7.1 nc (nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u> <u>Uteri Corpus and Uterus, NOS</u>
Male 5 4.0 125.5 (40.4-292.9)
Female 1 1.9 nc (nc-nc) Female 15 16.7 89.6 (50.1-147.8)
<u>Lung and Bronchus</u> All Sites / Types
Male 38 40.5 93.9 (66.5-128.9) Male 223 279.9 79.7 (69.6-90.8)
Female 49 41.2 119.0 (88.0-157.3) Female 305 299.3 101.9 (90.8-114.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

GrotonObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		vith Standardized Incidend				050/ 01
Bladder, Urinar	Obs	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	Molanoma of Skin	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Male	y 12	6.8	174 E	(91.1-308.3)	Melanoma of Skin Male	4	4.5	nc	(nc nc)
Female	0	2.2	176.5 nc	(nc-nc)	Female	3	3.7	nc	(nc-nc) (nc-nc)
Brain and Othe				(HC-HC)	Multiple Myeloma	3	3.1	nc	(110-110)
Male	<u>4</u>	<u>15 3yste</u> 1.7		(nc nc)	Male	0	1.1	nc	(nc nc)
Female	0	1.7	nc	(nc-nc) (nc-nc)	Female	0	0.7	nc	(nc-nc)
	U	1.4	nc	(IIC-IIC)			0.7	nc	(nc-nc)
<u>Breast</u> Male	0	0.2	nc	(nc-nc)	Non-Hodgkin Lymp Male	<u>110111a</u> 7	4.1	170.6	(68.3-351.5)
Female	43	30.6	nc 140.6	(101.8-189.5)	Female	3	3.3	nc	(nc-nc)
Cervix Uteri	43	30.0	140.0	(101.6-169.5)	Oral Cavity & Phary		3.3	IIC	(110-110)
Cervix Oteri					Male	4	3.2	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Colon / Rectum		1.0	TIC	(HC-HC)	<u>Ovary</u>	'	1.4	TIC	(110-110)
Male	<u>.</u> 12	10.8	111.1	(57.4-194.2)	<u>Ovary</u>				
Female	11	9.1	120.8	(60.2-216.2)	Female	1	3.1	nc	(nc-nc)
<u>Esophagus</u>		7.1	120.0	(00.2 210.2)	<u>Pancreas</u>	•	0.1	110	(110 110)
Male	1	1.9	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
Hodgkin Lympl		0		(1.5 1.6)	Prostate	·			(1.0 1.0)
Male	0	0.8	nc	(nc-nc)	Male Male	37	29 1	127.2	(89.5-175.3)
Female	0	0.6	nc	(nc-nc)	Maio	0,	27.1	127.2	(07.0 170.0)
Kidney & Rena				(**************************************	Stomach .				
Male	5	3.3	150.2	(48.4-350.4)	Male	1	1.8	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	2	2.5	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
Liver and Intral	hepatic E	Bile Duc	<u>:ts</u>		Uteri Corpus and U	terus, NOS	<u> </u>		
Male	0	1.6	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)	Female	5	5.9	84.6	(27.3-197.5)
Lung and Bron	<u>chus</u>				All Sites / Types				
Male	10	13.4	74.8	(35.8-137.6)	Male	105	99.3	105.8	(86.5-128.1)
Female	4	11.2	nc	(nc-nc)	Female	86	92.5	93.0	(74.4-114.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

GrovelandObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Inciden				050/ 01
Dioddon Ileinon	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>	Malanama of Chin	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary			102.0	(07 / 22/ /)	Melanoma of Skin	4	2.2		(no no)
Male	10	5.5	183.0	(87.6-336.6)	Male	4	3.2	nc	(nc-nc)
Female	1 . N	1.8	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
Brain and Other		-	 '	, ,	Multiple Myeloma				, ,
Male	4	1.2	nc	(nc-nc)	Male -	0	0.8	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymp				
Male	0	0.2	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	28	22.0	127.1	(84.4-183.6)	Female	2	2.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary				
					Male	0	2.3	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	11	8.5	130.1	(64.9-232.8)					
Female	11	7.3	151.2	(75.4-270.5)	Female	4	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	27	23.5	115.1	(75.8-167.4)
Female	0	0.4	nc	(nc-nc)					
Kidney & Renal	<u>Pelvis</u>				<u>Stomach</u>				
Male	2	2.5	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
Liver and Intrah	epatic E	Bile Duct	<u>s</u>		Uteri Corpus and Ut	erus, NOS	<u>.</u>		
Male	1	1.2	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)	Female	6	4.4	136.9	(50.0-297.9)
Lung and Brond	<u>chus</u>				All Sites / Types				
Male	12	10.8	111.4	(57.5-194.5)	Male	86	77.1	111.6	(89.2-137.8)
Female	15	9.0	167.2	(93.5-275.8)	Female	77	69.1	111.5	(88.0-139.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hadley
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		vith Standardized Incidend				050/ 01
D	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary	_				Melanoma of Skin				, ,
Male	4	6.9	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
Brain and Other	Nervou	ıs Systen	<u>1</u>		Multiple Myeloma				
Male	0	1.1	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	8.0	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymph	<u>noma</u>			
Male	1	0.2	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	26	23.9	108.8	(71.1-159.5)	Female	7	3.2	220.4	(88.3-454.2)
Cervix Uteri					Oral Cavity & Phary	<u>1x</u>			
					Male	4	2.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	9	10.3	87.4	(39.9-166.0)					
Female	11	10.7	102.7	(51.2-183.8)	Female	2	2.6	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	1	1.6	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
Hodgkin Lymph	<u>ioma</u>				<u>Prostate</u>				
Male	2	0.4	nc	(nc-nc)	Male	27	25.1	107.7	(70.9-156.7)
Female	0	0.4	nc	(nc-nc)					
Kidney & Renal	<u>Pelvis</u>				<u>Stomach</u>				
Male	2	2.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	2.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
Liver and Intrah	epatic E	Bile Ducts	<u> </u>		Uteri Corpus and Ut	erus, NOS	<u> </u>		
Male	1	1.2	nc	(nc-nc)					
Female	1	0.5	nc	(nc-nc)	Female	2	4.8	nc	(nc-nc)
Lung and Brond	<u>chus</u>				All Sites / Types				
Male	8	12.6	63.3	(27.3-124.7)	Male	84	86.2	97.4	(77.7-120.6)
Female	8	11.5	69.3	(29.9-136.6)	Female	81	83.0	97.6	(77.5-121.3)
				•					·

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Halifax
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	Obs O	Exp	and Expect	ged Case Courts, t 95% CI	With Standardized inclue	Obs	_	ა <u>SIR</u>	95% CI
Bladder, Urinar		<u>LXP</u>	SIK	45 /6 CI	Melanoma of Skin		<u>Exp</u>	SIK	93 /0 CI
Male	<u>y</u> 7	7.7	90.7	(36.3-186.9)	Male	3	4.3	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
Brain and Othe				(110-110)	Multiple Myeloma	4	3.0	TIC	(110-110)
Male	1	1.5		(nc nc)	Male Male	3	1 1	nc	(nc nc)
			nc	(nc-nc)		ა 1	1.1	nc	(nc-nc)
Female <u>Breast</u>	1	1.4	nc	(nc-nc)	Female Non-Hodgkin Lym		0.9	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Male	3	4.0	nc	(nc nc)
			nc oz o					nc	(nc-nc)
Female	30	30.7	97.9	(66.0-139.7)	Female	4	3.7	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pha		2.0		(
	4	1.1		,	Male	3	3.0	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Colon / Rectum	_				<u>Ovary</u>				
Male	14	11.8	118.7	(64.8-199.2)					
Female	15	11.3	132.4	(74.1-218.4)	Female	6	3.2	187.2	(68.3-407.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.0	nc	(nc-nc)	Male	5	2.2	223.4	(72.0-521.2)
Female	0	0.5	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
Hodgkin Lympl	<u>homa</u>				<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	28	31.8	88.0	(58.5-127.2)
Female	1	0.6	nc	(nc-nc)					
Kidney & Rena	<u>l Pelvis</u>				<u>Stomach</u>				
Male	5	3.3	152.1	(49.0-354.9)	Male	2	2.0	nc	(nc-nc)
Female	6	2.1	282.8	(103.3-615.5)	Female	2	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	3	1.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	4	2.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	5	2.1	243.3	(78.4-567.7)	Female	0	3.0	nc	(nc-nc)
Liver and Intral	nepatic I	Bile Duct	t <u>s</u>		Uteri Corpus and	Uterus, N	<u>os</u>		
Male	0	1.5	nc	(nc-nc)					
Female	1	0.6	nc	(nc-nc)	Female	7	6.2	112.4	(45.0-231.7)
Lung and Bron	chus				All Sites / Types				
Male	16	14.8	108.3	(61.9-175.9)	Male	107	104.9	102.0	(83.6-123.3)
Female	16	13.6	117.4	(67.0-190.6)	Female	116	100.2		(95.6-138.8)
				. ,					•

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incid				0E% CI
Bladder, Urinar	Obs	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	Melanoma of Skin	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Male	y 6	7.8	76.5	(28.0-166.6)	Male	7	4.5	155.0	(62.1-319.5)
Female	2	2.5	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
Brain and Othe				(110-110)	Multiple Myeloma	7	5.0	TIC	(110-110)
Male	4	1.7	nc	(nc-nc)	Male Male	1	1.2	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Breast	2	1.5	IIC	(IIC-IIC)	Non-Hodgkin Lym		0.0	ПС	(110-110)
Male	1	0.3	nc	(nc-nc)	Male	5	43	117.4	(37.8-274.1)
Female	34	29.7	114.3	(79.2-159.8)	Female	3	3.4	nc	(nc-nc)
Cervix Uteri	31	27.7	111.5	(17.2 107.0)	Oral Cavity & Phar		3.1	110	(no no)
OGI VIN OTOTI					Male	9 8	3.2	249.9	(107.6-492.4)
Female	3	1.5	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Colon / Rectum				(/	<u>Ovary</u>				(/
Male	- 15	12.0	124.6	(69.7-205.5)					
Female	14	9.9	141.9	(77.5-238.2)	Female	3	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.0	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	6	2.1	288.9	(105.5-628.8)
Hodgkin Lympl	<u>homa</u>				<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	21	32.4	64.9	(40.1-99.2)
Female	1	0.6	nc	(nc-nc)					
Kidney & Rena	<u>l Pelvis</u>				Stomach Stomach				
Male	3	3.4	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.4	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	6	2.6	231.5	(84.5-503.8)	Male	1	1.0	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
Liver and Intral			<u>s</u>		Uteri Corpus and I	Jterus, N	<u>os</u>		
Male	1	1.6	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)	Female	5	5.9	84.1	(27.1-196.4)
Lung and Bron					All Sites / Types				
Male	6	15.2	39.6	(14.5-86.2)	Male	96	108.0	88.9	(72.0-108.5)
Female	8	12.3	65.1	(28.0-128.2)	Female	102	93.9	108.6	(88.6-131.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003 <u>Obs</u> 95% CI **Exp** <u>SIR</u> Obs SIR 95% CI <u>Exp</u> Bladder, Urinary Melanoma of Skin Male 6 5.7 104.9 (38.3-228.4)Male 2 3.2 nc (nc-nc) 3 Female 2.0 (nc-nc) Female 1 2.5 nc (nc-nc) nc **Brain and Other Nervous System** Multiple Myeloma 0 Male 1 1.1 nc (nc-nc) Male 8.0 nc (nc-nc) 2 0.9 0 Female nc (nc-nc) Female 0.7 nc (nc-nc) Non-Hodgkin Lymphoma **Breast** 0 Male 0.2 nc (nc-nc) Male 3.0 (nc-nc) nc Female 28 22.2 126.0 (83.7-182.1)Female 1 2.6 (nc-nc) nc Cervix Uteri Oral Cavity & Pharynx Male 1 2.3 (nc-nc) nc Female 1 (nc-nc) 3 1.0 nc (nc-nc) Female 1.1 nc Colon / Rectum Ovary Male (25.0-149.2) 6 8.8 68.5 Female 7 8.2 85.5 (34.2-176.1)Female 2 2.3 nc (nc-nc) **Esophagus Pancreas** Male 1 1.5 nc (nc-nc) Male 0 1.7 nc (nc-nc) Female 0 0.4 nc (nc-nc) Female 2 1.7 nc (nc-nc) Hodgkin Lymphoma **Prostate** Male 0 0.4 Male 25 24.4 102.4 (nc-nc) (66.2-151.2)nc Female 0 0.4 (nc-nc) nc Kidney & Renal Pelvis Stomach Male 2 2.5 Male 1 1.5 (nc-nc) nc (nc-nc) nc Female 0 1.5 0 0.9 nc (nc-nc) Female nc (nc-nc) **Testis Larynx** Male 0 1 1.1 nc (nc-nc) Male 0.7 nc (nc-nc) Female 0 0.3 nc (nc-nc) <u>Leukemia</u> **Thyroid** 0 0 Male 1.8 nc (nc-nc) Male 0.6 nc (nc-nc) Female 1 1.5 Female 4 2.0 nc (nc-nc) nc (nc-nc) **Liver and Intrahepatic Bile Ducts** Uteri Corpus and Uterus, NOS Male 0 1.2 nc (nc-nc) Female 0 0.4 nc (nc-nc) Female 1 4.5 nc (nc-nc) Lung and Bronchus All Sites / Types Male 9 81.0 (37.0-153.7)Male 78.8 (60.4-101.0) 11.1 62 78.7

• Obs = observed case count; Exp = expected case count;

178.4

9.5

17

Female

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(103.8-285.6)

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Female

76

71.7 105.9

(83.5-132.6)

Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003 95% CI Obs **Exp** SIR <u>Obs</u> <u>Exp</u> <u>SIR</u> 95% CI Bladder, Urinary Melanoma of Skin Male 1 0.9 (nc-nc) Male 0 0.5 nc (nc-nc) nc 0 Female 0.3 nc (nc-nc) Female 0 0.3 nc (nc-nc) Brain and Other Nervous System Multiple Myeloma Male 0 Male 0 0.1 0.2 nc (nc-nc) nc (nc-nc) 0 0.1 Female 0 0.1 Female nc (nc-nc) nc (nc-nc) **Breast** Non-Hodgkin Lymphoma 0 0 0.4 Male 0.0 (nc-nc) Male nc (nc-nc) nc Female 3 3.1 (nc-nc) Female 0 0.4 (nc-nc) nc nc Cervix Uteri Oral Cavity & Pharynx Male 0 0.4 (nc-nc) nc 0 Female 1 0.1 Female 0.1 (nc-nc) nc (nc-nc) nc Colon / Rectum Ovary Male 1 1.3 (nc-nc) nc Female 1 1.1 nc (nc-nc) Female 0 0.3 nc (nc-nc) **Pancreas Esophagus** 0 Male 0 0.2 nc (nc-nc) Male 0.3 nc (nc-nc) Female 0 0.1 nc (nc-nc) Female 0 0.2 nc (nc-nc) Hodgkin Lymphoma **Prostate** Male 0 0.1 Male 3 3.8 (nc-nc) nc (nc-nc) nc 0 Female 0.0 (nc-nc) nc Kidney & Renal Pelvis **Stomach** 0 Male 1 0.4 Male 0.2 (nc-nc) nc (nc-nc) nc 0 (nc-nc) Female 0 Female 0.1 0.2 nc (nc-nc) nc <u>Larynx</u> <u>Testis</u> 0 Male 0 0.2 0.1 nc (nc-nc) Male nc (nc-nc) Female 0 0.0 nc (nc-nc) **Leukemia Thyroid** 0 0 0.1 Male 0.3 (nc-nc) Male nc (nc-nc) nc Female 0 0.2 Female 0 0.3 (nc-nc) (nc-nc) nc nc Uteri Corpus and Uterus, NOS Liver and Intrahepatic Bile Ducts Male 0 0.2 (nc-nc) nc Female 0 0.1 0 0.6 nc (nc-nc) Female nc (nc-nc) Lung and Bronchus All Sites / Types Male 0 Male 12.1 49.6 (18.1-107.9) 1.7 (nc-nc) 6 nc

• Obs = observed case count; Exp = expected case count;

1.3

nc

3

Female

- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

(nc-nc)

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

10

Female

9.8

101.7

(48.7-187.1)

Hanover
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•	•	with Standardized Incide				250/ 21
DI 11 11.	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	M I (OI)	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary	-			(22 = 122 ()	Melanoma of Skin				(00 0 00 00 0)
Male	8	11.3	70.8	(30.5-139.6)	Male	11	6.9	160.5	(80.0-287.2)
Female	6	4.4	137.8	(50.3-300.0)	Female	6	5.9	101.7	(37.1-221.3)
Brain and Other		-	<u>m</u>		<u>Multiple Myeloma</u>				
Male	2	2.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	0	0.4	nc	(nc-nc)	Male	2	6.4	nc	(nc-nc)
Female	60	51.2	117.2	(89.4-150.8)	Female	8	5.9	135.2	(58.2-266.4)
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>			
					Male	7	5.1	137.5	(55.1-283.4)
Female	2	2.3	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	21	17.7	118.6	(73.4-181.3)					
Female	22	17.8	123.9	(77.6-187.5)	Female	6	5.3	113.2	(41.3-246.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.1	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
Hodgkin Lympho	<u>oma</u>				<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	53	49.9	106.1	(79.5-138.8)
Female	1	0.9	nc	(nc-nc)					
Kidney & Renal	<u>Pelvis</u>				<u>Stomach</u>				
Male	7	5.3	132.1	(52.9-272.1)	Male	1	3.0	nc	(nc-nc)
Female	7	3.4	204.3	(81.8-420.9)	Female	1	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	3	2.2	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	3	3.9	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	Female	10	5.0	200.0	(95.7-367.8)
Liver and Intrahe	epatic E	Bile Duct	<u>s</u>		Uteri Corpus and L	Jterus, N	<u>os</u>		
Male	1	2.5	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)	Female	10	10.4	96.3	(46.1-177.0)
Lung and Bronc	<u>hus</u>				All Sites / Types				
Male	20	22.3	89.6	(54.7-138.3)	Male	163	162.6	100.2	(85.4-116.9)
Female	17	21.5	79.1	(46.1-126.7)	Female	181	162.9	111.1	(95.5-128.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanson
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incide				000/ 01
Diaddan Udaa	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	Malanana af Chin	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urina		7.0	150.0	(70.4.0(0.4)	Melanoma of Skin		4.0		()
Male	12	7.8	153.8	(79.4-268.6)	Male	4	4.8	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	5	4.0	125.3	(40.4-292.4)
Brain and Othe		-		, ,	Multiple Myeloma	_			,
Male	3	1.8	nc	(nc-nc)	Male	5	1.2		(134.9-977.0)
Female	3	1.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	0	0.3	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	37	33.5	110.5	(77.8-152.3)	Female	2	3.7	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pha	<u>rynx</u>			
					Male	6	3.6	167.9	(61.3-365.5)
Female	0	1.6	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
Colon / Rectun	<u>n</u>				<u>Ovary</u>				
Male	21	12.3	171.3	(106.0-261.8)					
Female	13	10.6	122.2	(65.0-209.0)	Female	2	3.4	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	4	2.1	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Hodgkin Lymp</u>	<u>homa</u>				<u>Prostate</u>				
Male	0	8.0	nc	(nc-nc)	Male	27	34.8	77.5	(51.0-112.7)
Female	0	0.7	nc	(nc-nc)					
Kidney & Rena	<u>Il Pelvis</u>				<u>Stomach</u>				
Male	1	3.7	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	4	2.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	7	3.6	195.6	(78.4-403.1)
Liver and Intra	hepatic	Bile Duc	<u>ts</u>		Uteri Corpus and	Uterus, N	<u> </u>		
Male	3	1.7	nc	(nc-nc)					
Female	1	0.5	nc	(nc-nc)	Female	9	6.8	132.5	(60.5-251.5)
Lung and Bron	<u>ichus</u>				All Sites / Types				
Male	26	15.5	167.3	(109.3-245.2)	Male	135	113.5	119.0	(99.7-140.8)
Female	26	13.3	195.6	(127.7-286.6)	Female	121	103.9	116.5	(96.6-139.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		vith Standardized Inciden				050/ 01
Dioddon Ileinon	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	Malanama of Chin	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar		2.0		()	Melanoma of Skin	0	1 5		(
Male	4	2.8	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
Brain and Othe		_		, ,	Multiple Myeloma				, ,
Male	1	0.6	nc	(nc-nc)	Male 	0	0.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lympl				
Male	0	0.1	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	12	10.4	115.3	(59.5-201.4)	Female	1	1.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary				
					Male	2	1.1	nc	(nc-nc)
Female	3	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Colon / Rectum	<u> </u>				<u>Ovary</u>				
Male	4	4.3	nc	(nc-nc)					
Female	6	4.2	142.8	(52.1-310.7)	Female	1	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	8.0	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	11	11.4	96.4	(48.1-172.6)
Female	0	0.2	nc	(nc-nc)					
Kidney & Renal	<u>Pelvis</u>				<u>Stomach</u>				
Male	0	1.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Liver and Intrah	<u>nepatic E</u>	Bile Ducts	<u>S</u>		Uteri Corpus and Ut	erus, NOS	<u> </u>		
Male	0	0.6	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
Lung and Brone	<u>chus</u>				All Sites / Types				
Male	8	5.4	147.2	(63.4-290.0)	Male	37	38.1	97.2	(68.4-134.0)
Female	4	4.8	nc	(nc-nc)	Female	44	35.1	125.3	(91.1-168.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harvard
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Inciden				050/ 01
Dioddon History	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>	Malanama of Chin	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar Male		E 7	10E 2	(20.4.220.0)	Melanoma of Skin	_	2.0	120.2	(41 / 201 E)
	6 1	5.7	105.2	(38.4-228.9)	Male Female	5 1	3.9 2.5	129.2	(41.6-301.5)
Female		1.5	nc ~	(nc-nc)		1	2.5	nc	(nc-nc)
Brain and Othe		_		, ,	Multiple Myeloma	4	0.0		()
Male	2	1.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>		0.0		, ,	Non-Hodgkin Lymp		0.5		, ,
Male	1	0.2	nc	(nc-nc)	Male -	0	3.5	nc	(nc-nc)
Female	22	21.6	101.6	(63.7-153.9)	Female	1	2.2	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary				
				, ,	Male .	3	2.9	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	9	9.2	98.3	(44.9-186.6)					
Female	8	6.1	131.9	(56.8-259.9)	Female	5	2.2	230.4	(74.3-537.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.6	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Hodgkin Lymph	<u>homa</u>				<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	29	25.7	112.7	(75.5-161.8)
Female	0	0.4	nc	(nc-nc)					
Kidney & Rena	<u>l Pelvis</u>				<u>Stomach</u>				
Male	7	2.9	243.4	(97.5-501.6)	Male	2	1.5	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	2	2.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
Liver and Intrah	nepatic I	Bile Duct	<u>s</u>		Uteri Corpus and U	terus, NOS	<u>i</u>		
Male	3	1.4	nc	(nc-nc)					
Female	1	0.3	nc	(nc-nc)	Female	9	4.4	204.5	(93.3-388.3)
Lung and Bron	<u>chus</u>				All Sites / Types				
Male	12	11.4	105.7	(54.6-184.7)	Male	95	85.6	110.9	(89.8-135.6)
Female	4	7.9	nc	(nc-nc)	Female	64	63.8	100.3	(77.2-128.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			-	95% CI	With Standardized incid				<u>95% CI</u>
Bladder, Urinar	Obs	<u>Exp</u>	<u>SIR</u>	93 / CI	Melanoma of Skin	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>43 /6 CI</u>
Male	y 34	25.0	136.0	(94.2-190.0)	Male	16	10.0	146.1	(83.5-237.3)
Female	11	9.2	119.7	(59.7-214.1)	Female	11		131.5	(65.5-235.2)
				(39.7-214.1)			0.4	131.3	(00.0-230.2)
Brain and Othe		-		()	Multiple Myeloma		2.4		, ,
Male	4	3.4	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	Female	. 2	3.0	nc	(nc-nc)
<u>Breast</u>				, ,	Non-Hodgkin Lym				((0.0.000.5)
Male -	1	0.7	nc	(nc-nc)	Male .	13	11.0	118.4	(63.0-202.5)
Female	79	78.7	100.4	(79.5-125.1)	Female	8	11.0	72.5	(31.2-142.9)
Cervix Uteri					Oral Cavity & Pha	<u>rynx</u>			
					Male	6	7.5	79.9	(29.2-173.9)
Female	2	2.8	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
Colon / Rectum	<u>1</u>				<u>Ovary</u>				
Male	26	36.5	71.3	(46.5-104.4)					
Female	47	38.2	123.1	(90.4-163.6)	Female	5	8.6	58.3	(18.8-136.0)
Esophagus					<u>Pancreas</u>				
Male	8	5.7	141.2	(60.8-278.2)	Male	8	6.9	116.8	(50.3-230.1)
Female	0	1.8	nc	(nc-nc)	Female	9	8.2	110.1	(50.2-209.0)
<u>Hodgkin Lympl</u>	<u>noma</u>				<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	127	92.3	137.6	(114.7-163.7)
Female	0	1.0	nc	(nc-nc)					
Kidney & Rena	l Pelvis				<u>Stomach</u>				
Male	12	8.8	136.7	(70.5-238.8)	Male	5	6.2	80.6	(26.0-188.1)
Female	6	6.1	98.2	(35.9-213.8)	Female	3	4.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	4	3.8	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	6	6.8	88.3	(32.2-192.2)	Male	2	1.7	nc	(nc-nc)
Female	8	6.0	133.1	(57.3-262.2)	Female	5	5.2	95.9	(30.9-223.8)
Liver and Intral	nepatic I	Bile Duct	ts_		Uteri Corpus and	Uterus, N	<u>IOS</u>		
Male	3	4.0	nc	(nc-nc)	·				
Female	0	1.8	nc	(nc-nc)	Female	17	16.3	104.6	(60.9-167.5)
Lung and Bron	<u>chus</u>				All Sites / Types				
Male	38	45.6	83.3	(58.9-114.3)	Male	339	303.7	111.6	(100.0-124.1)
Female	37	42.2	87.7	(61.8-120.9)	Female	273	283.9	96.2	(85.1-108.3)
				•					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incidence				050/ 01
DI 11 11:	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	M 1 (C):	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar	_			, ,	Melanoma of Skin				, ,
Male	3	4.3	nc	(nc-nc)	Male -	4	2.3	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Brain and Othe		-	<u>n</u>		Multiple Myeloma				
Male	1	8.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymph	<u>noma</u>			
Male	0	0.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	17	15.6	109.1	(63.5-174.7)	Female	1	1.9	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary	<u>1X</u>			
					Male	5	1.7	301.0	(97.0-702.4)
Female	0	0.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Colon / Rectum	<u>l</u>				<u>Ovary</u>				
Male	3	6.6	nc	(nc-nc)					
Female	5	6.2	81.2	(26.2-189.4)	Female	1	1.6	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	2	1.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	4	1.3	nc	(nc-nc)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	3	0.3	nc	(nc-nc)	Male	17	17.5	97.1	(56.5-155.5)
Female	0	0.2	nc	(nc-nc)					
Kidney & Renal	l Pelvis				<u>Stomach</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Liver and Intrah	nepatic E	Bile Ducts	<u>s</u>		Uteri Corpus and Ut	erus, NOS	<u>i</u>		
Male	0	0.8	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
Lung and Bron	<u>chus</u>				All Sites / Types				
Male	7	8.3	84.5	(33.9-174.2)	Male	55	57.4	95.8	(72.1-124.7)
Female	6	7.2	83.2	(30.4-181.1)	Female	47	51.7	90.8	(66.7-120.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Haverhill
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incide				OEO/ CI
Bladder, Urina	Obs	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	Melanoma of Skin	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Male	42	54.5	77.0	(55.5-104.1)	Male	16	30.1	53.2	(30.4-86.4)
Female	17	22.3	76.3	(44.4-122.2)	Female	16	27.3	58.5	(33.4-95.0)
Brain and Oth				(44.4-122.2)	Multiple Myeloma	10	21.3	30.3	(33.4-93.0)
Male	10	11.0	90.8	(43.5-167.0)	Male	4	7.9	nc	(nc nc)
Female	10	10.5	95.3		Female	4	7.9	nc 82.9	(nc-nc)
	10	10.5	90.3	(45.6-175.3)		6 nhoma	1.2	02.9	(30.3-180.4)
Breast Male	1	17	no	(no no)	Non-Hodgkin Lym		20.0	74.4	(47.0.115.4)
Male	1	1.7	nc or o	(nc-nc) (83.5-109.5)	Male Female	22	28.8	76.4	(47.8-115.6)
Female	217	226.4	95.9	(83.5-109.5)		34	29.1	116.6	(80.8-163.0)
Cervix Uteri					Oral Cavity & Phar	-	20.5	02.5	(FF 7 1 4 4 4)
Famala	11	10 F	10E 1	(E2 4 100 O)	Male	19	20.5	92.5	(55.7-144.4)
Female	11	10.5	105.1	(52.4-188.0)	Female	9	11.5	78.4	(35.8-148.9)
Colon / Rectur		02.7	04.2	(74 / 117 7)	<u>Ovary</u>				
Male Female	78 04	82.7 93.1	94.3 100.9	(74.6-117.7)	Female	22	24.2	90.9	(E7 O 127 7)
	94	93.1	100.9	(81.6-123.5)		22	24.2	90.9	(57.0-137.7)
Esophagus Mala	10	10.4	00.7	(4/ 2 15/ 0)	<u>Pancreas</u>	15	15 /	0/ 4	(F2.0.1F0.0)
Male	12	13.4	89.7	(46.3-156.8)	Male	15	15.6	96.4	(53.9-159.0)
Female	9	4.4	203.8	(93.0-386.8)	Female	18	19.6	91.9	(54.5-145.3)
Hodgkin Lymp		F 0		, ,	<u>Prostate</u>	100	011 7	0/ 5	(74.4.00.0)
Male	4	5.0	nc	(nc-nc)	Male	183	211.7	86.5	(74.4-99.9)
Female	6 - 1 D - 1 - 1 -	4.6	130.1	(47.5-283.1)	Ctamaala				
Kidney & Rena			100.4	(00 0 100 F)	<u>Stomach</u>	10	141	00.4	(40.2.150.0)
Male	30	22.5	133.4	(90.0-190.5)	Male	13	14.1	92.4	(49.2-158.0)
Female	8	16.1	49.6	(21.4-97.8)	Female	11	10.0	110.1	(54.9-197.0)
<u>Larynx</u>	-	0.0	75.4	(20.0.155.4)	<u>Testis</u>	-	0.5	74.0	(00.7.450.5)
Male	7	9.3	75.4	(30.2-155.4)	Male	7	9.5	74.0	(29.7-152.5)
Female	4	2.8	nc	(nc-nc)	Thomasa				
<u>Leukemia</u>	47	17.0	05.4	(FF F 4F0 7)	<u>Thyroid</u>				, ,
Male	17	17.8	95.4	(55.5-152.7)	Male	4	6.3	nc	(nc-nc)
Female	14	16.8	83.5	(45.6-140.0)	Female	13	22.5	57.8	(30.7-98.8)
Liver and Intra	•			(45.7.475.7)	Uteri Corpus and L	<u>Jterus, N</u>	<u>IOS</u>		
Male	10	10.5	95.5	(45.7-175.7)	F 1		45.0	140.1	(100 4 101 5)
Female	. 4	4.5	nc	(nc-nc)	Female	64	45.0	142.1	(109.4-181.5)
Lung and Bron		100.0	0.4.4	/7/ 0.114.0\	All Sites / Types	(50	705.0	00.7	(00.0.04.0)
Male	96	102.0	94.1	(76.2-114.9)	Male 	650	725.0	89.7	(82.9-96.8)
Female	101	103.6	97.5	(79.4-118.4)	Female	742	771.0	96.2	(89.4-103.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003 95% CI <u>Obs</u> <u>Exp</u> SIR Obs <u>Exp</u> <u>SIR</u> 95% CI Bladder, Urinary Melanoma of Skin Male 1 0.6 (nc-nc) Male 0 0.3 nc (nc-nc) nc Female 0 0.1 nc (nc-nc) Female 0 0.2 nc (nc-nc) **Brain and Other Nervous System** Multiple Myeloma Male 1 Male 0 0.1 0.1 nc (nc-nc) nc (nc-nc) 0.1 (nc-nc) Female 0 0.0 Female 0 nc nc (nc-nc) Non-Hodgkin Lymphoma **Breast** Male 0 0.0 (nc-nc) Male 0.3 nc (nc-nc) nc Female 0 1.5 (nc-nc) Female 0 0.2 (nc-nc) nc nc Cervix Uteri Oral Cavity & Pharynx Male 0 0.2 (nc-nc) nc 0 Female 0 0.1 Female 0.1 (nc-nc) nc (nc-nc) nc Colon / Rectum Ovary Male 8.0 0 (nc-nc) nc Female 0 0.5 nc (nc-nc) Female 0 0.2 nc (nc-nc) **Esophagus Pancreas** Male 0 0.1 nc (nc-nc) Male 0 0.2 nc (nc-nc) Female 0 0.0 nc (nc-nc) Female 0 0.1 nc (nc-nc) Hodgkin Lymphoma **Prostate** Male 0 0.0 Male 2.4 (nc-nc) 1 (nc-nc) nc nc Female 0 0.0 (nc-nc) nc Kidney & Renal Pelvis Stomach Male 0 0.2 Male 0 0.1 (nc-nc) nc (nc-nc) nc Female 0.1 Female 0 0.1 0 nc (nc-nc) nc (nc-nc) <u>Larynx</u> **Testis** 0 0 Male 0.1 nc (nc-nc) Male 0.0 nc (nc-nc) Female 0 0.0 nc (nc-nc) <u>Leukemia</u> **Thyroid** 0 Male 0 0.2 (nc-nc) Male 0.1 nc (nc-nc) nc Female 0 0.1 Female 0 0.1 (nc-nc) (nc-nc) nc nc Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 0 0.1 (nc-nc) nc Female 0.0 0 0 nc (nc-nc) Female 0.3 nc (nc-nc) Lung and Bronchus All Sites / Types Male 0 Male 5 7.4 67.1 (21.6-156.7) 1.1 (nc-nc) nc 0 0.6 Female nc (nc-nc) Female 4.8 nc (nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Heath

	Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003								
	<u>Obs</u>	<u>Exp</u>	SIR	95% CI		<u>Obs</u>	<u>Exp</u>	SIR	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	0	0.9	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Brain and Other N	ervous Sy	<u>rstem</u>			Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lympho	<u>oma</u>			
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharyn	<u>x</u>			
					Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Colon / Rectum					<u>Ovary</u>				
Male	0	1.3	nc	(nc-nc)					
Female	1	0.9	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Hodgkin Lymphon	<u>na</u>				<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pe	<u>elvis</u>				<u>Stomach</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	2	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Liver and Intrahep	atic Bile D	<u>Oucts</u>			Uteri Corpus and Ute	rus, NOS			
Male	0	0.2	nc	(nc-nc)					
Female	0	0.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Lung and Bronchu	<u>IS</u>				All Sites / Types				
Male	3	1.7	nc	(nc-nc)	Male	10	12.2	81.7	(39.1-150.3)
Female	0	1.2	nc	(nc-nc)	Female	9	9.2	97.3	(44.4-184.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

<u>Obs</u> Ехр <u>SIR</u> 95% CI Obs <u>Exp</u> <u>SIR</u> 95% CI Bladder, Urinary Melanoma of Skin Male 23 22.2 103.4 (65.5-155.2)Male 22 12.1 181.6 (113.8-275.0)Female 9 8.5 105.6 (48.2-200.5)Female 22 10.2 215.8 (135.2-326.7)**Brain and Other Nervous System** Multiple Myeloma 2 Male 3 4.3 nc (nc-nc) Male 3.3 nc (nc-nc) 3.9 Female 3 2.8 Female 4 nc (nc-nc) nc (nc-nc) Non-Hodgkin Lymphoma **Breast** Male 0 0.7 nc (nc-nc) Male 15 11.5 130.7 (73.1-215.7)Female 108 91.4 118.2 (97.0-142.7)Female 9 11.1 81.4 (37.1-154.6)Cervix Uteri Oral Cavity & Pharynx Male 2 8.9 nc (nc-nc) Female 3.9 6 4.5 133.5 3 nc (nc-nc) Female (48.8-290.7)Colon / Rectum Ovary Male 35 34.1 102.8 (71.6-142.9)Female 29 35.1 82.7 (55.3-118.7)Female 8 9.6 83.5 (35.9-164.5)**Esophagus Pancreas** Male 3 8 5.7 139.8 (60.2-275.5)Male 6.5 nc (nc-nc) 94.9 Female 2 1.7 nc (nc-nc) Female 7 7.4 (38.0-195.6)Hodgkin Lymphoma **Prostate** Male Male 89 93.8 94.8 1 1.6 (nc-nc) (76.2-116.7)nc Female 1 1.4 (nc-nc) nc Kidney & Renal Pelvis Stomach Male 10 9.6 104.2 (49.9-191.6)Male 2 5.7 (nc-nc) nc Female Female 0 3.7 10 6.3 158.0 (75.7-290.6)nc (nc-nc) **Larynx Testis** Male 2.7 1 4.1 nc (nc-nc) Male 4 nc (nc-nc) Female 2 1.1 nc (nc-nc) **Leukemia Thyroid** 3 Male 10 7.0 142.9 (68.4-262.8)Male 2.4 nc (nc-nc) Female 2 Female 10 7.9 126.1 (60.4-231.9)6.2 (nc-nc) nc **Liver and Intrahepatic Bile Ducts** Uteri Corpus and Uterus, NOS Male 2 4.5 nc (nc-nc) Female 1 1.7 nc (nc-nc) Female 21 18.7 112.1 (69.4-171.4)Lung and Bronchus All Sites / Types Male 53.4 (33.8-80.1)Male 274 90.3 (79.9-101.6) 23 43.1 303.6 35 Female 40.7 86.0 (59.9-119.7)Female 311 299.9 103.7 (92.5-115.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hinsdale
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		vith Standardized Inciden				
	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar	_				Melanoma of Skin				
Male	2	2.0	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	1	8.0	nc	(nc-nc)
Brain and Other	r Nervou	<u>is Systen</u>	<u>n</u>		Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lympl	<u>noma</u>			
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	6	7.3	82.7	(30.2-180.0)	Female	1	0.8	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary	<u>nx</u>			
					Male	2	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Colon / Rectum	<u> </u>				<u>Ovary</u>				
Male	3	3.0	nc	(nc-nc)					
Female	6	2.5	238.4	(87.1-518.9)	Female	4	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	11	8.7	126.6	(63.1-226.6)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal	Pelvis				<u>Stomach</u>				
Male	2	0.9	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Liver and Intrah	nepatic B	Bile Ducts	<u>S</u>		Uteri Corpus and Ut	erus, NOS			
Male	0	0.4	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Lung and Brond	<u>chus</u>				All Sites / Types				
Male	1	3.9	nc	(nc-nc)	Male	33	27.8	118.9	(81.8-166.9)
Female	3	3.1	nc	(nc-nc)	Female	28	23.2	120.8	(80.2-174.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holbrook
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	SIR	95% CI	with Standardized inclue	Obs	5, 1777 200 <u>Exp</u>	SIR	95% CI	
Bladder, Urinary					Melanoma of Skin					
Male	8	12.9	62.1	(26.8-122.4)	Male	3	6.7	nc	(nc-nc)	
Female	6	4.6	129.8	(47.4-282.4)	Female	3	5.5	nc	(nc-nc)	
Brain and Other	Nervou	ıs Syster	<u>n</u>		Multiple Myeloma					
Male	1	2.3	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)	
Female	4	2.1	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)	
<u>Breast</u>					Non-Hodgkin Lymphoma					
Male	0	0.4	nc	(nc-nc)	Male	5	6.5	77.2	(24.9-180.2)	
Female	45	47.4	95.0	(69.3-127.1)	Female	6	6.0	100.5	(36.7-218.7)	
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>				
					Male	6	4.7	126.7	(46.3-275.9)	
Female	3	2.1	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)	
Colon / Rectum					<u>Ovary</u>					
Male	22	19.4	113.5	(71.1-171.9)						
Female	14	18.5	75.8	(41.4-127.1)	Female	7	5.0	139.8	(56.0-288.1)	
Esophagus					<u>Pancreas</u>					
Male	6	3.2	188.2	(68.7-409.7)	Male	2	3.7	nc	(nc-nc)	
Female	1	0.9	nc	(nc-nc)	Female	5	4.0	126.0	(40.6-294.0)	
Hodgkin Lymphoma					<u>Prostate</u>					
Male	4	1.0	nc	(nc-nc)	Male	43	52.9	81.3	(58.8-109.5)	
Female	0	8.0	nc	(nc-nc)						
Kidney & Renal	<u>Pelvis</u>				<u>Stomach</u>					
Male	1	5.3	nc	(nc-nc)	Male	5	3.2	154.7	(49.9-361.1)	
Female	1	3.4	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)	
<u>Larynx</u>					<u>Testis</u>					
Male	5	2.2	224.0	(72.2-522.8)	Male	1	1.7	nc	(nc-nc)	
Female	1	0.6	nc	(nc-nc)						
<u>Leukemia</u>					<u>Thyroid</u>					
Male	4	4.0	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)	
Female	6	3.2	185.5	(67.7-403.8)	Female	3	4.3	nc	(nc-nc)	
<u>Liver and Intrahepatic Bile Ducts</u>				Uteri Corpus and L	<u>Jterus, NC</u>	<u>)S</u>				
Male	5	2.4	204.8	(66.0-478.0)						
Female	1	0.9	nc	(nc-nc)	Female	11	9.8	112.5	(56.1-201.3)	
Lung and Brond					All Sites / Types					
Male	32	24.8	128.9	(88.2-182.0)	Male	168	171.7	97.8	(83.6-113.8)	
Female	30	22.7	132.1	(89.1-188.7)	Female	163	159.0	102.5	(87.4-119.5)	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

HoldenObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		vitti Standardized incide				050/ 01	
	<u>Obs</u>	<u>Exp</u>	SIR	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	
Bladder, Urinar					Melanoma of Skin					
Male	17	18.3	92.9	(54.1-148.7)	Male	8	9.8	81.7	(35.2-161.0)	
Female	6	6.4	93.7	(34.2-204.0)	Female	7	7.7	90.9	(36.4-187.3)	
Brain and Other	Nervou	ıs Syster	<u>n</u>		Multiple Myeloma					
Male	5	3.4	145.5	(46.9-339.4)	Male	3	2.7	nc	(nc-nc)	
Female	5	3.0	167.9	(54.1-391.9)	Female	3	2.1	nc	(nc-nc)	
<u>Breast</u>					Non-Hodgkin Lymphoma					
Male	0	0.6	nc	(nc-nc)	Male	8	9.4	85.5	(36.8-168.5)	
Female	69	68.4	100.9	(78.5-127.7)	Female	6	8.4	71.7	(26.2-156.1)	
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>				
					Male	5	7.1	70.1	(22.6-163.7)	
Female	0	3.0	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)	
Colon / Rectum					<u>Ovary</u>					
Male	18	27.9	64.5	(38.2-102.0)						
Female	19	26.5	71.7	(43.2-112.0)	Female	12	7.2	167.2	(86.3-292.1)	
<u>Esophagus</u>					<u>Pancreas</u>					
Male	2	4.6	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)	
Female	0	1.3	nc	(nc-nc)	Female	2	5.6	nc	(nc-nc)	
Hodgkin Lymphoma				<u>Prostate</u>						
Male	1	1.3	nc	(nc-nc)	Male	57	74.3	76.7	(58.1-99.4)	
Female	2	1.1	nc	(nc-nc)						
Kidney & Renal Pelvis					Stomach Stomach					
Male	2	7.7	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)	
Female	3	4.8	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)	
<u>Larynx</u>					<u>Testis</u>					
Male	3	3.2	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)	
Female	0	0.8	nc	(nc-nc)						
<u>Leukemia</u>				, ,	<u>Thyroid</u>					
Male	8	5.7	140.5	(60.5-276.8)	Male	2	1.9	nc	(nc-nc)	
Female	3	4.7	nc	(nc-nc)	Female	8	6.1	131.3	(56.6-258.8)	
Liver and Intrahepatic Bile Ducts					Uteri Corpus and L				,	
Male	4	3.6	nc	(nc-nc)						
Female	0	1.3	nc	(nc-nc)	Female	16	13.8	115.7	(66.1-188.0)	
	Lung and Bronchus								. ,	
Male	24	34.8	68.9	(44.1-102.5)	All Sites / Types Male	188	244.9	76.8	(66.2-88.6)	
Female	20	30.6	65.3	(39.9-100.8)	Female	199	225.4	88.3	(76.4-101.4)	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holland
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			-	ged Case Courts, w 95% CI	itti Standardized incidenc			SIR	95% CI
Bladder, Urinar	Obs	<u>Exp</u>	<u>SIR</u>	93 /6 CI	Melanoma of Skin	<u>Obs</u>	<u>Exp</u>	SIK	93 /0 CI
Male	y 8	2.1	378.1	(162.8-745.0)	Male	0	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Brain and Othe				(HC-HC)	Multiple Myeloma	U	1.0	IIC	(110-110)
Male	0	0.5	nc	(nc-nc)	Male Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)				nc	
Breast	U	0.4	IIC	(HC-HC)	Female 0 0.2 nc (nc-nc) Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	<u>10111a</u> 2	1.2	nc	(nc-nc)
Female	5	7.9	63.5	(20.5-148.2)	Female	1	0.9		(nc-nc)
Cervix Uteri	5	1.9	03.3	(20.5-146.2)	Oral Cavity & Phary		0.9	nc	(110-110)
Cervix Oteri					Male	0	1.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female		0.4	nc	(nc-nc)
Colon / Rectum		0.4	nc	(IIC-IIC)		0	0.4	nc	(110-110)
Male	9	3.3	270.5	(123.4-513.5)	<u>Ovary</u>				
Female	5	2.4	211.2	(68.1-492.9)	Female	2	0.8	nc	(nc-nc)
Esophagus	J	2.4	211.2	(00.1-472.7)	<u>Pancreas</u>	2	0.0	IIC	(110-110)
<u>Lsopriagus</u> Male	0	0.6	nc	(nc-nc)	<u>rancreas</u> Male	0	0.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Hodgkin Lymph	-	0.1	IIC	(HC-HC)		1	0.5	IIC	(110-110)
Male	<u>10111a</u> 0	0.2	no	(no no)	<u>Prostate</u> Male	8	9.0	88.4	(38.1-174.2)
Female	0	0.2	nc	(nc-nc) (nc-nc)	ividle	0	9.0	00.4	(30.1-174.2)
Kidney & Renal		0.2	nc	(HC-HC)	<u>Stomach</u>				
Male	2	1.0	nc	(nc-nc)	<u>Stornach</u> Male	0	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
	'	0.5	IIC	(110-110)	<u>Testis</u>	U	0.2	TIC	(110-110)
<u>Larynx</u> Male	0	0.4	nc	(nc-nc)	<u>resus</u> Male	1	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Walc	'	0.4	TIC	(110-110)
<u>Leukemia</u>	U	0.1	IIC	(110-110)	<u>Thyroid</u>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Liver and Intrah				(ne ne)	Uteri Corpus and Ut			110	(HC HC)
Male	0	0.5	nc	(nc-nc)	oteri corpus ana ot	crus, NOS	<u>2</u>		
Female	0	0.1	nc	(nc-nc)	Female	4	1.6	nc	(nc-nc)
Lung and Bron		٠		(1.6 1.6)	All Sites / Types	•			()
Male	3	4.1	nc	(nc-nc)	Male	36	30.2	119.1	(83.4-164.9)
Female	6	3.0	199.1	(72.7-433.3)	Female	26		108.2	(70.7-158.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	Obs O	Exp	and Expect	eu Case Courts, v 95% CI	viin Standardized incide	Obs	s, 1999-200 <u>Exp</u>	ه SIR	95% CI		
Bladder, Urinary Melanoma of Skin							<u>/3/0 CI</u>				
Male	<u>.</u> 16	11.6	138.3	(79.0-224.6)	Male	11	7.3	151.6	(75.6-271.3)		
Female	2	3.9	nc	(nc-nc)	Female	7		116.4	(46.6-239.8)		
Brain and Othe	r Nervoi			, ,	Multiple Myeloma	· · · · · · · · · · · · · · · · · · ·					
Male	2	2.7	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)		
Female	1	2.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)		
<u>Breast</u>					Non-Hodgkin Lym	Non-Hodgkin Lymphoma					
Male	1	0.4	nc	(nc-nc)	Male	7	6.7	104.9	(42.0-216.1)		
Female	69	51.7	133.3	(103.7-168.8)	Female	4	5.5	nc	(nc-nc)		
Cervix Uteri					Oral Cavity & Pha	rynx					
					Male	5	5.5	91.6	(29.5-213.7)		
Female	5	2.5	200.8	(64.7-468.6)	Female	2	2.4	nc	(nc-nc)		
Colon / Rectum	<u>1</u>				<u>Ovary</u>						
Male	21	18.3	115.0	(71.2-175.8)							
Female	11	15.6	70.4	(35.1-126.1)	Female	3	5.2	nc	(nc-nc)		
Esophagus					<u>Pancreas</u>						
Male	3	3.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)		
Female	2	8.0	nc	(nc-nc)	Female	6	3.3	184.4	(67.3-401.4)		
<u>Hodgkin Lympl</u>	<u>homa</u>				<u>Prostate</u>						
Male	0	1.1	nc	(nc-nc)	Male	59	52.8	111.7	(85.0-144.1)		
Female	1	0.9	nc	(nc-nc)							
Kidney & Renal Pelvis					<u>Stomach</u>						
Male	5	5.6	88.8	(28.6-207.3)	Male	4	3.0	nc	(nc-nc)		
Female	3	3.3	nc	(nc-nc)	Female	4	1.6	nc	(nc-nc)		
<u>Larynx</u>					<u>Testis</u>						
Male	2	2.3	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)		
Female	0	0.6	nc	(nc-nc)							
<u>Leukemia</u>				, ,	<u>Thyroid</u>				, ,		
Male	4	4.0	nc	(nc-nc)	Male -	0	1.6	nc	(nc-nc)		
Female	1	3.1	nc	(nc-nc)	Female	6		111.6	(40.8-242.9)		
Liver and Intrahepatic Bile Ducts					Uteri Corpus and	<u>Uterus, N</u>	<u>OS</u>				
Male	3	2.7	nc	(nc-nc)	Famala	10	10.5	1140	(FO 2 200 ()		
Female	2	8.0	nc	(nc-nc)	Female	12	10.5	114.8	(59.3-200.6)		
Lung and Bron		22.2	0/ 0	(E) E 122.0\	All Sites / Types	100	170.0	10/ 0	(02.0.122.7)		
Male	20	23.3	86.0	(52.5-132.8)	Male	182	170.2		(92.0-123.6)		
Female	16	20.0	79.9	(45.6-129.7)	Female	171	157.1	108.8	(93.1-126.4)		

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holyoke
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

<u>Obs</u> Ехр SIR 95% CI Obs <u> Exp</u> SIR 95% CI Bladder, Urinary Melanoma of Skin Male 43 43.6 98.7 (71.4-132.9)Male 14 21.6 64.7 (35.3-108.6)9 Female 17.4 51.7 (23.6-98.2)Female 22 18.9 116.5 (73.0-176.4)**Brain and Other Nervous System** Multiple Myeloma 7.8 Male 2 Male 4 nc (nc-nc) 6.2 nc (nc-nc) 2 5 7.6 Female 5.6 Female 66.1 (21.3-154.3)nc (nc-nc) Non-Hodgkin Lymphoma **Breast** Male 1 1.3 nc (nc-nc) Male 15 21.3 70.4 (39.3-116.1)Female 139 161.0 86.3 (72.6-101.9) Female 18 21.9 82.0 (48.6-129.7)Cervix Uteri Oral Cavity & Pharynx Male 21 14.7 142.5 (88.2-217.8)7 Female 8.5 82.5 Female 8 6.8 117.6 (50.6-231.7) (33.0-169.9)Colon / Rectum Ovary (88.2-141.4) Male 73 64.9 112.5 Female 65 73.6 88.3 (68.1-112.6)Female 15 17.6 85.3 (47.7-140.7)**Esophagus Pancreas** Male 12 10.2 117.3 (60.5-204.8)Male 10 12.2 82.0 (39.2-150.7)Female 3 3.5 nc (nc-nc) Female 19 15.5 122.5 (73.7-191.4)Hodgkin Lymphoma **Prostate** Male 3 3.2 Male 78.5 (65.5-93.4)(nc-nc) 128 163.0 nc Female 1 3.1 nc (nc-nc) Kidney & Renal Pelvis Stomach Male 13 78.1 (41.5-133.6) Male 14 11.0 126.8 (69.3-212.8)16.6 9 Female 7 87.4 Female 12.0 75.1 (34.3-142.6)8.0 (35.0-180.0)**Larynx** <u>Testis</u> 9 Male 7.0 128.4 (58.6-243.7)Male 6 5.4 111.0 (40.5-241.5)Female 3 2.0 (nc-nc) nc **Leukemia Thyroid** Male 12 13.5 88.6 (45.7-154.8)Male 4 4.1 nc (nc-nc) Female 8 12.8 62.3 (26.8-122.7) Female 8 14.2 56.2 (24.2-110.7)Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 7 7.7 91.2 (36.5-187.8)Female 2 3.5 nc (nc-nc) Female 43 32.4 132.8 (96.1-178.8)Lung and Bronchus All Sites / Types Male 91 80.2 Male 554.6 93.2 (85.4-101.6) 113.4 (91.3-139.3)517 570.5 91.5 Female 84 78.6 106.9 (85.2-132.3)Female 522 (83.8-99.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003 95% CI <u>Obs</u> <u>Exp</u> SIR <u>Obs</u> <u>Exp</u> SIR 95% CI Bladder, Urinary Melanoma of Skin Male 7 6.8 103.0 (41.3-212.2) Male 2 3.5 nc (nc-nc) 0 Female 2.5 (nc-nc) Female 2 2.9 (nc-nc) nc nc **Brain and Other Nervous System** Multiple Myeloma Male 2 Male 0 1.2 nc (nc-nc) 1.0 nc (nc-nc) 3 1.1 Female 4 nc (nc-nc) Female 8.0 nc (nc-nc) Non-Hodgkin Lymphoma **Breast** Male 0 0.2 nc (nc-nc) Male 2 3.4 nc (nc-nc) Female 29 25.4 114.4 (76.6-164.3)Female 1 3.2 (nc-nc) nc Cervix Uteri Oral Cavity & Pharynx Male 0 2.4 (nc-nc) nc Female 1 1.3 (nc-nc) Female 1 1.1 nc (nc-nc) nc Colon / Rectum Ovary Male 10.2 4 (nc-nc) nc Female 6 10.5 57.0 (20.8-124.1)Female 2 2.7 nc (nc-nc) **Pancreas Esophagus** Male 2 1.6 nc (nc-nc) Male 4 1.9 nc (nc-nc) Female 0 0.5 nc (nc-nc) Female 3 2.2 nc (nc-nc) Hodgkin Lymphoma **Prostate** Male 0 0.5 21 25.3 82.9 (51.3-126.7) (nc-nc) Male nc Female 0 0.4 (nc-nc) nc Kidney & Renal Pelvis Stomach Male 1 2.7 Male 0 1.7 (nc-nc) nc (nc-nc) nc 7 Female 1.8 386.8 (155.0-797.0)0 1.1 Female nc (nc-nc) **Larynx** <u>Testis</u> 2 0.9 Male 1 1.1 nc (nc-nc) Male nc (nc-nc) Female 0 0.3 nc (nc-nc) Leukemia **Thyroid** 2 0 Male 2.1 (nc-nc) Male 0.7 nc (nc-nc) nc Female 2 1.8 Female 1 2.3 nc (nc-nc) (nc-nc) nc **Liver and Intrahepatic Bile Ducts** Uteri Corpus and Uterus, NOS Male 1 1.3 (nc-nc) nc Female 0 0.5 nc (nc-nc) Female 1 5.0 nc (nc-nc) Lung and Bronchus All Sites / Types Male 127.4 (72.8-206.9)Male 76 87.3 87.1 (68.6-109.0)12.6 16 7 11.7 59.7 78 Female (23.9-123.1)Female 86.0 90.7 (71.7-113.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

HopkintonObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			-		with Standardized inclu				0E% CI
Dladdar Urinar	Obs	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>	Malanama of Chin	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar Male	y 5	0.7	FO 4	(10.0.12/.2)	Melanoma of Skin Male	<u>.</u> 7	г 0	110 /	(47 5 244 4)
		8.6	58.4	(18.8-136.2)				118.6	(47.5-244.4)
Female	2	3.1	nc	(nc-nc)	Female	7	5.1	136.5	(54.7-281.2)
Brain and Othe		-		, ,	Multiple Myeloma				, ,
Male 	1	2.3	nc	(nc-nc)	Male .	0	1.4	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym				
Male	0	0.3	nc	(nc-nc)	Male	7	5.4	130.5	(52.3-268.8)
Female	48	41.5	115.8	(85.4-153.5)	Female	3	4.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pha	<u>rynx</u>			
					Male	3	4.3	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
Colon / Rectum	<u>1</u>				<u>Ovary</u>				
Male	8	13.8	58.2	(25.0-114.6)					
Female	11	12.7	86.9	(43.3-155.5)	Female	7	4.2	166.7	(66.8-343.5)
Esophagus					<u>Pancreas</u>				
Male	1	2.4	nc	(nc-nc)	Male	7	2.6	267.8	(107.3-551.9)
Female	2	0.6	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
Hodgkin Lympl	<u>homa</u>				<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	37	37.0	99.9	(70.3-137.7)
Female	0	0.8	nc	(nc-nc)					
Kidney & Rena	l Pelvis				Stomach .				
Male	3	4.4	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	1.7	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	5	3.3	152.5	(49.1-355.8)	Male	1	1.4	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	3	4.9	nc	(nc-nc)
Liver and Intral	nepatic I		s	,	Uteri Corpus and	Uterus, N	os		, ,
Male	3	2.1	nc nc	(nc-nc)		•			
Female	0	0.6	nc	(nc-nc)	Female	7	7.9	89.0	(35.6-183.3)
Lung and Bron	<u>chu</u> s			. ,	All Sites / Types				. ,
Male	19	16.9	112.2	(67.5-175.2)	Male	117	127.7	91.7	(75.8-109.8)
Female	15	15.1	99.4	(55.6-163.9)	Female	132		104.5	(87.4-123.9)
				,					(/

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Ехр</u>	SIR	95% CI	Mili Standardized melden	Obs	.,,,, <u>Ехр</u>	SIR	95% CI
Bladder, Urinar	<u>y</u>				Melanoma of Skin				
Male	6	2.7	222.8	(81.4-484.9)	Male	0	1.8	nc	(nc-nc)
Female	0	8.0	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Brain and Othe	r Nervou	ıs System	<u>1</u>		Multiple Myeloma				
Male	2	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lympl	<u>homa</u>			
Male	1	0.1	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	11	11.7	94.3	(47.0-168.7)	Female	0	1.2	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary	<u>nx</u>			
					Male	1	1.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Colon / Rectum	<u>1</u>				<u>Ovary</u>				
Male	2	4.3	nc	(nc-nc)					
Female	5	3.4	145.6	(46.9-339.8)	Female	1	1.2	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	3	8.0	nc	(nc-nc)	Male	1	8.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Hodgkin Lympl	<u>noma</u>				<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	15	12.0	125.0	(69.9-206.2)
Female	0	0.3	nc	(nc-nc)					
Kidney & Rena	l Pelvis				<u>Stomach</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	3	1.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Liver and Intral			<u>i</u>		Uteri Corpus and Ut	erus, NOS	•		
Male	0	0.6	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
Lung and Bron					All Sites / Types				
Male	4	5.4	nc	(nc-nc)	Male	43	40.3	106.8	(77.2-143.8)
Female	4	4.2	nc	(nc-nc)	Female	35	35.3	99.2	(69.1-138.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

HudsonObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized inclue		_		OEO/ CI
Dladdar Urinar	Obs	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	Molonomo of Ckin	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar		17 F	12/ 0	(70.0.100.0)	Melanoma of Skin	7	10.1	/O.3	(27.0.142.0)
Male	22	17.5	126.0	(78.9-190.8)	Male	7	10.1	69.3	(27.8-142.8) (E7.0.210.1)
Female	8 • Now.ex	6.5	123.9	(53.3-244.1)	Female	10	8.4	119.1	(57.0-219.1)
Brain and Othe				, ,	Multiple Myeloma	0	0.7		()
Male	4	3.7	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	. 3	2.1	nc	(nc-nc)
<u>Breast</u>				,	Non-Hodgkin Lym				,
Male	0	0.6	nc	(nc-nc)	Male	7	9.5	73.9	(29.6-152.2)
Female	58	71.1	81.5	(61.9-105.4)	Female	7	8.6	81.2	(32.5-167.3)
Cervix Uteri					Oral Cavity & Phar				
					Male	5	7.2	69.3	(22.3-161.8)
Female	5	3.3	152.1	(49.0-355.0)	Female	6	3.5	172.0	(62.8-374.3)
Colon / Rectum	<u>l</u>				<u>Ovary</u>				
Male	37	26.9	137.6	(96.9-189.7)					
Female	25	26.1	95.9	(62.1-141.6)	Female	7	7.4	94.1	(37.7-193.8)
Esophagus					<u>Pancreas</u>				
Male	5	4.5	110.0	(35.4-256.7)	Male	5	5.1	97.9	(31.6-228.5)
Female	0	1.3	nc	(nc-nc)	Female	6	5.5	108.7	(39.7-236.5)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	1	1.6	nc	(nc-nc)	Male	70	74.6	93.9	(73.2-118.6)
Female	0	1.3	nc	(nc-nc)					
Kidney & Renal	Pelvis				<u>Stomach</u>				
Male	7	7.7	90.4	(36.2-186.2)	Male	2	4.5	nc	(nc-nc)
Female	3	4.9	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	3.2	nc	(nc-nc)	Male	5	3.0	164.1	(52.9-382.9)
Female	1	0.9	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	9	5.7	157.3	(71.8-298.5)	Male	1	2.2	nc	(nc-nc)
Female	6	4.8	126.0	(46.0-274.3)	Female	3	7.0	nc	(nc-nc)
Liver and Intrah	nepatic I	Bile Duct	<u>s</u>		Uteri Corpus and I	Jterus, NO	<u>os</u>		
Male	3	3.6	nc	(nc-nc)	•				
Female	0	1.3	nc	(nc-nc)	Female	14	14.5	96.5	(52.7-162.0)
Lung and Bron	<u>chus</u>				All Sites / Types				,
Male	43	34.1	126.1	(91.2-169.9)	Male	249	243.9	102.1	(89.8-115.6)
Female	39	31.8	122.5	(87.1-167.5)	Female	221	232.9	94.9	(82.8-108.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hull
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incide				050/ 01
DI 11 11.	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urina		11 (1/40	(00.0.057.7)	Melanoma of Skin			10/ 5	(104 = 227.0)
Male	19	11.6	164.3	(98.9-256.6)	Male	13	6.6	196.5	(104.5-336.0)
Female	9	3.9	230.6	(105.2-437.8)	Female	5	5.4	92.4	(29.8-215.7)
Brain and Othe		_	<u>em</u>		<u>Multiple Myeloma</u>				
Male	2	2.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	0	0.4	nc	(nc-nc)	Male	6	6.2	96.7	(35.3-210.4)
Female	59	46.9	125.9	(95.8-162.4)	Female	8	5.3	150.3	(64.7-296.2)
Cervix Uteri					Oral Cavity & Phar	<u>rynx</u>			
					Male	8	4.8	165.4	(71.2-325.9)
Female	0	2.2	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
Colon / Rectun	<u>1</u>				<u>Ovary</u>				
Male	23	17.9	128.8	(81.6-193.2)					
Female	22	15.6	141.1	(88.4-213.7)	Female	9	4.8	187.1	(85.4-355.2)
Esophagus					<u>Pancreas</u>				
Male	4	3.0	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
Female	2	8.0	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
Hodgkin Lymp	<u>homa</u>				<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	50	49.6	100.7	(74.7-132.8)
Female	1	8.0	nc	(nc-nc)					
Kidney & Rena	I Pelvis				<u>Stomach</u>				
Male	4	5.1	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	6	3.1	192.8	(70.4-419.7)	Female	3	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	5	2.1	233.2	(75.2-544.2)	Male	1	1.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	7	3.7	189.2	(75.8-389.8)	Male	4	1.4	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	6	4.6	129.9	(47.4-282.8)
Liver and Intra	hepatic	Bile Duc	ts.		Uteri Corpus and I	Uterus, N	<u>0S</u>		
Male	2	2.4	nc	(nc-nc)	·				
Female	2	0.8	nc	(nc-nc)	Female	9	9.6	93.5	(42.7-177.5)
Lung and Bron	<u>ichus</u>				All Sites / Types				
Male	26	22.6	115.2	(75.3-168.9)	Male	194	161.1	120.4	(104.0-138.6)
Female	42	19.7	213.2	(153.6-288.2)	Female	199	147.4	135.0	(116.9-155.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

HuntingtonObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Ехр</u>	SIR	95% CI	mii Standardized incident	Obs	.,,, <u>Ехр</u>	SIR	95% CI
Bladder, Urinar	У				Melanoma of Skin				
Male	4	2.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Brain and Other	r Nervou	s Systen	<u>1</u>		Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymph	<u>noma</u>			
Male	0	0.1	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	12	7.8	153.7	(79.3-268.6)	Female	1	0.9	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary	<u>1x</u>			
					Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Colon / Rectum	<u> </u>				<u>Ovary</u>				
Male	3	3.1	nc	(nc-nc)					
Female	0	2.7	nc	(nc-nc)	Female	2	8.0	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	3	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	8.6	57.9	(18.7-135.2)
Female	1	0.2	nc	(nc-nc)					
Kidney & Renal	Pelvis				<u>Stomach</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	2	8.0	nc	(nc-nc)
Liver and Intrah	•				Uteri Corpus and Ut	<u>erus, NOS</u>			
Male	0	0.4	nc	(nc-nc)					, ,
Female	0	0.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Lung and Brone				, .	All Sites / Types	0-		0.5 -	/== a :
Male	3	3.9	nc	(nc-nc)	Male	25	28.4	88.0	(57.0-130.0)
Female	4	3.2	nc	(nc-nc)	Female	30	24.7	121.2	(81.8-173.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

IpswichObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		with Standardized Incide				050/ 01
DI 11 11.	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>	M 1 (01)	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar		45.0		(,,,,,,===)	Melanoma of Skin				/= 0 0 0 0 0 0 N
Male	16	15.0	106.9	(61.1-173.7)	Male	9	8.2	110.2	(50.3-209.3)
Female	4	6.0	nc	(nc-nc)	Female	9	6.9	130.1	(59.4-246.9)
Brain and Othe		_	<u>m</u>		<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	0	0.5	nc	(nc-nc)	Male	9	7.7	116.6	(53.2-221.3)
Female	69	61.8	111.6	(86.9-141.3)	Female	7	7.7	91.0	(36.4-187.4)
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>			
					Male	2	5.9	nc	(nc-nc)
Female	0	2.6	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
Colon / Rectum	<u> </u>				<u>Ovary</u>				
Male	18	22.9	78.6	(46.6-124.3)					
Female	31	24.9	124.6	(84.7-176.9)	Female	6	6.5	91.9	(33.6-200.0)
Esophagus					<u>Pancreas</u>				
Male	2	3.8	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	4	5.2	nc	(nc-nc)
<u>Hodgkin Lympl</u>	<u>noma</u>				<u>Prostate</u>				
Male	4	1.1	nc	(nc-nc)	Male	66	61.8	106.7	(82.5-135.8)
Female	0	1.0	nc	(nc-nc)					
Kidney & Renal	<u>Pelvis</u>				<u>Stomach</u>				
Male	12	6.4	187.8	(96.9-328.1)	Male	2	3.8	nc	(nc-nc)
Female	2	4.3	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	2.7	nc	(nc-nc)	Male	5	1.9	268.7	(86.6-627.0)
Female	1	0.8	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	4	4.6	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	6	4.3	140.8	(51.4-306.5)	Female	2	5.3	nc	(nc-nc)
Liver and Intrah	nepatic I	Bile Duct	<u>s</u>		Uteri Corpus and I	Jterus, NO	<u>os</u>		
Male	3	3.0	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)	Female	14	12.5	111.6	(61.0-187.2)
Lung and Brone	<u>chus</u>				All Sites / Types				
Male	24	28.9	83.1	(53.2-123.7)	Male	196	202.5	96.8	(83.7-111.3)
Female	36	28.2	127.4	(89.2-176.4)	Female	223	206.3	108.1	(94.4-123.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

KingstonObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Ехр</u>	SIR	95% CI	vitri Staridardized iricidei	Obs	<u>Exp</u>	SIR	95% CI
Bladder, Urinar	у				Melanoma of Skin				
Male	14	12.3	114.2	(62.4-191.6)	Male	10	6.6	151.8	(72.7-279.3)
Female	12	4.5	267.7	(138.2-467.7)	Female	5	5.5	90.8	(29.3-211.9)
Brain and Othe	r Nervo	us Syste	<u>m</u>		Multiple Myeloma				
Male	2	2.4	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	0	0.4	nc	(nc-nc)	Male	5	6.3	79.0	(25.5-184.4)
Female	52	46.6	111.6	(83.3-146.3)	Female	6	5.9	102.3	(37.3-222.6)
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>			
					Male	4	4.6	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
Colon / Rectum	<u>1</u>				<u>Ovary</u>				
Male	20	18.6	107.6	(65.7-166.1)					
Female	14	18.8	74.5	(40.7-125.0)	Female	9	4.9	182.0	(83.1-345.6)
Esophagus					<u>Pancreas</u>				
Male	2	3.0	nc	(nc-nc)	Male	7	3.5	199.7	(80.0-411.4)
Female	1	0.9	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<u>Hodgkin Lympl</u>	<u>homa</u>				<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	48	47.4	101.3	(74.7-134.3)
Female	0	0.9	nc	(nc-nc)					
Kidney & Rena	<u>l Pelvis</u>				<u>Stomach</u>				
Male	9	5.0	179.3	(81.8-340.4)	Male	2	3.1	nc	(nc-nc)
Female	6	3.3	183.5	(67.0-399.4)	Female	4	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	2.1	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	3.9	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	Female	7		156.0	(62.5-321.4)
Liver and Intral	-		<u>ts</u>		Uteri Corpus and I	<u>Jterus, N</u>	<u>os</u>		
Male	2	2.3	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)	Female	2	9.2	nc	(nc-nc)
Lung and Bron					All Sites / Types				
Male	34	22.9	148.2	(102.6-207.1)	Male	182	161.4		(97.0-130.4)
Female	18	20.9	86.3	(51.1-136.4)	Female	161	156.5	102.9	(87.6-120.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

LakevilleObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Ехр</u>	SIR	95% CI	vitri Staridardized irielde	Obs	, 1777 <u>Ехр</u>	SIR	<u>95% CI</u>
Bladder, Urinar	<u>y</u>				Melanoma of Skin				
Male	10	9.1	110.2	(52.8-202.7)	Male	4	5.3	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	7	4.4	158.1	(63.3-325.8)
Brain and Other	r Nervou	ıs Syster	<u>n</u>		Multiple Myeloma				
Male	4	1.9	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	4	1.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	ohoma			
Male	0	0.3	nc	(nc-nc)	Male	3	5.0	nc	(nc-nc)
Female	31	37.6	82.4	(56.0-117.0)	Female	4	4.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>			
					Male	7	3.8	182.5	(73.1-376.1)
Female	0	1.8	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
Colon / Rectum	<u> </u>				<u>Ovary</u>				
Male	18	14.0	128.4	(76.1-203.0)					
Female	10	14.1	71.1	(34.1-130.8)	Female	0	3.9	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	0	2.4	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
Hodgkin Lymph	<u>noma</u>				<u>Prostate</u>				
Male	0	8.0	nc	(nc-nc)	Male	37	38.0	97.3	(68.5-134.1)
Female	1	0.7	nc	(nc-nc)					
Kidney & Renal	Pelvis				<u>Stomach</u>				
Male	5	4.1	123.4	(39.8-287.9)	Male	3	2.4	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	1.7	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	3.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
Liver and Intrah	<u>nepatic E</u>		<u>s</u>		Uteri Corpus and L	<u>Iterus, NC</u>	<u>)S</u>		
Male	2	1.9	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)	Female	8	7.4	107.7	(46.4-212.2)
Lung and Brone					All Sites / Types				
Male	24	17.5	137.2	(87.9-204.1)	Male	133	126.2		(88.2-124.9)
Female	16	15.9	100.9	(57.6-163.9)	Female	98	122.4	80.0	(65.0-97.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lancaster
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			-	95% CI	With Standardized incluent			SIR	95% CI
Bladder, Urinar	Obs v	<u>Exp</u>	<u>SIR</u>	93 % CI	Melanoma of Skin	<u>Obs</u>	<u>Exp</u>	SIK	73 /0 CI
Male	y 3	6.3	nc	(nc-nc)	Male	6	4.0	148.7	(54.3-323.6)
Female	4	2.2	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
Brain and Othe				(110-110)	Multiple Myeloma	2	2.7	TIC	(110-110)
Male	2	1.5		(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	3	1.5	nc nc	(nc-nc)	Female	2	0.7		(nc-nc)
Breast	3	1.1	IIC	(110-110)	Non-Hodgkin Lymph		0.7	nc	(110-110)
Male	0	0.2	nc	(nc-nc)	<u>Male</u> Male	<u>10111a</u> 2	3.7	nc	(nc-nc)
Female	23	23.9	96.1	(60.9-144.3)	Female	1	2.9		(nc-nc)
Cervix Uteri	23	23.9	90.1	(00.9-144.3)			2.9	nc	(110-110)
Cervix Oteri					Oral Cavity & Phary Male	2	2.8	nc	(nc nc)
Female	1	1.1	nc	(nc nc)	Female	2	1.2	nc	(nc-nc) (nc-nc)
		1.1	nc	(nc-nc)		Z	1.2	nc	(110-110)
Colon / Rectum Male	<u>.</u> 8	9.9	80.8	(34.8-159.1)	<u>Ovary</u>				
Female	8	9.9	87.2	(34.6-139.1)	Female	1	2.5	nc	(nc-nc)
Esophagus	U	7.2	07.2	(37.3-171.7)	<u>Pancreas</u>	'	2.5	TIC	(110-110)
<u>Lsopriagus</u> Male	4	1.7	nc	(nc-nc)	<u>rancreas</u> Male	2	1.9	nc	(nc-nc)
Female	0	0.4	nc nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
Hodgkin Lymph		0.4	TIC	(IIC-IIC)	Prostate	'	1.7	TIC	(110-110)
Male	<u>10111a</u> 1	0.0	nc	(nc nc)	<u>Frostate</u> Male	22	26.5	82.9	(51.9-125.5)
Female	1	0.8 0.5	nc nc	(nc-nc) (nc-nc)	iviale	22	20.3	02.9	(31.9-123.3)
Kidney & Renal		0.5	IIC	(HC-HC)	Stomach Stomach				
Male	1	2.9	nc	(nc-nc)	<u>stomach</u> Male	1	1.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Larynx</u>	'	1.0	TIC	(110-110)	<u>Testis</u>	'	1.0	TIC	(110-110)
Male	1	1.2	nc	(nc-nc)	<u>resus</u> Male	0	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Walc	U	1.0	TIC	(110-110)
<u>Leukemia</u>	U	0.5	TIC	(ne ne)	<u>Thyroid</u>				
Male	1	2.2	nc	(nc-nc)	Male Male	1	0.9	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
Liver and Intrah				(He He)	Uteri Corpus and Ut			TIC	(He He)
Male	0	1.4	<u>s</u> nc	(nc-nc)	oten corpus and ot	crus, Noc	<u>.</u>		
Female	0	0.4	nc	(nc-nc)	Female	6	4.8	125.6	(45.9-273.3)
Lung and Bron		0		(1.0 1.0)	All Sites / Types	Ü		.20.0	(1017 27010)
Male	<u></u> 11	12.3	89.8	(44.7-160.6)	Male	72	90.6	79.5	(62.2-100.1)
Female	11	10.4	105.9	(52.8-189.5)	Female	76	79.1	96.1	(75.7-120.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

LanesboroughObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		vith Standardized Incidend				0=0/ 0:
51 11 111	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinar	_				Melanoma of Skin				, ,
Male	2	3.6	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Brain and Othe	r Nervou	ıs Systen	<u>n</u>		Multiple Myeloma				
Male	1	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lymph	<u>noma</u>			
Male	1	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	19	12.4	153.5	(92.4-239.7)	Female	2	1.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phary	<u>1X</u>			
					Male	1	1.4	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Colon / Rectum	<u>l</u>				<u>Ovary</u>				
Male	5	5.4	91.8	(29.6-214.3)					
Female	5	4.4	114.3	(36.8-266.8)	Female	2	1.3	nc	(nc-nc)
Esophagus					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Hodgkin Lympl	<u>noma</u>				<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	15	14.9	100.7	(56.3-166.2)
Female	1	0.2	nc	(nc-nc)					
Kidney & Rena	l Pelvis				<u>Stomach</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Liver and Intral	nepatic E	Bile Ducts	<u>s</u>		Uteri Corpus and Ut	erus, NOS	<u>1</u>		
Male	1	0.7	nc	(nc-nc)					
Female	1	0.2	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
Lung and Bron	<u>chus</u>				All Sites / Types				
Male	4	6.9	nc	(nc-nc)	Male	46	48.5	94.9	(69.5-126.6)
Female	3	5.4	nc	(nc-nc)	Female	45	39.7	113.4	(82.7-151.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lawrence
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

		Jbserved a	•		vith Standardized Incider		s, 1999-200		
	<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Ехр</u>	SIR	<u>95% CI</u>
Bladder, Urina	<u>ary</u>				Melanoma of Skin				
Male	43	53.5	80.4	(58.2-108.3)	Male	14	30.2	46.4	(25.3-77.8)
Female	26	21.8	119.5	(78.0-175.1)	Female	12	28.2	42.6	(22.0-74.4)
Brain and Oth	er Nervo	ous Syster	<u>m</u>		Multiple Myeloma				
Male	11	12.0	92.0	(45.9-164.7)	Male	5	7.8	64.2	(20.7-149.9)
Female	10	11.3	88.5	(42.4-162.8)	Female	4	7.1	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>ohoma</u>			
Male	1	1.7	nc	(nc-nc)	Male	26	29.1	89.2	(58.3-130.8)
Female	162	224.6	72.1	(61.4-84.1)	Female	33	29.1	113.4	(78.0-159.3)
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>			
					Male	30	20.3	147.6	(99.6-210.7)
Female	26	10.8	240.8	(157.3-352.9)	Female	8	11.5	69.9	(30.1-137.7)
Colon / Rectu	<u>m</u>				<u>Ovary</u>				
Male	84	81.2	103.4	(82.5-128.0)					
Female	73	91.2	80.0	(62.7-100.6)	Female	25	24.2	103.2	(66.8-152.4)
Esophagus					<u>Pancreas</u>				
Male	14	13.1	106.9	(58.4-179.3)	Male	23	15.3	150.6	(95.5-226.0)
Female	8	4.3	185.5	(79.9-365.5)	Female	14	19.1	73.3	(40.0-122.9)
Hodgkin Lym	<u>ohoma</u>				<u>Prostate</u>				
Male	6	5.9	102.4	(37.4-222.9)	Male	193	206.6	93.4	(80.7-107.6)
Female	7	5.5	126.2	(50.5-259.9)					
Kidney & Ren	al Pelvis	<u>i</u>			<u>Stomach</u>				
Male	11	22.3	49.4	(24.6-88.5)	Male	19	13.9	137.0	(82.5-214.0)
Female	10	16.0	62.4	(29.9-114.7)	Female	6	9.8	61.1	(22.3-133.0)
<u>Larynx</u>					<u>Testis</u>				
Male	9	9.1	99.0	(45.2-188.0)	Male	6	11.0	54.6	(19.9-118.8)
Female	5	2.8	181.6	(58.5-423.9)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	18	18.7	96.3	(57.0-152.1)	Male	3	6.6	nc	(nc-nc)
Female	15	17.6	85.3	(47.7-140.6)	Female	16	24.2	66.2	(37.8-107.6)
Liver and Intra	<u>ahepatic</u>	Bile Duct	<u>s</u>		Uteri Corpus and L	Jterus, N	<u>IOS</u>		
Male	14	10.3	135.5	(74.0-227.4)					
Female	5	4.5	112.2	(36.1-261.7)	Female	50	44.5	112.4	(83.4-148.2)
Lung and Bro	<u>nchus</u>				All Sites / Types				
Male	112	99.7	112.3	(92.5-135.2)	Male	688	718.8	95.7	(88.7-103.1)
Female	80	101.2	79.1	(62.7-98.4)	Female	657	768.1	85.5	(79.1-92.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lee
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

			•		vith Standardized Incide				
	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Ехр</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinai	<u>ry</u>				Melanoma of Skin				
Male	4	7.7	nc	(nc-nc)	Male	9	4.0	227.0	(103.6-430.9)
Female	2	2.7	nc	(nc-nc)	Female	5	3.1	161.7	(52.1-377.3)
Brain and Othe	r Nervo	us Syste	<u>m</u>		Multiple Myeloma				
Male	0	1.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					Non-Hodgkin Lym	<u>phoma</u>			
Male	0	0.2	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	34	27.5	123.8	(85.7-173.0)	Female	4	3.5	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Phar	<u>ynx</u>			
					Male	3	2.8	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
Colon / Rectum	<u>1</u>				<u>Ovary</u>				
Male	16	11.6	138.3	(79.0-224.6)					
Female	23	11.1	207.8	(131.7-311.8)	Female	0	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.9	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Hodgkin Lymp	<u>homa</u>				<u>Prostate</u>				
Male	2	0.6	nc	(nc-nc)	Male	24	31.2	77.0	(49.3-114.6)
Female	1	0.4	nc	(nc-nc)					
Kidney & Rena	I Pelvis				Stomach Stomach				
Male	7	3.1	224.8	(90.1-463.2)	Male	1	1.9	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	1.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	2.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
Liver and Intra	hepatic I	Bile Duc	<u>ts</u>		Uteri Corpus and I	Jterus, N	<u>IOS</u>		
Male	2	1.4	nc	(nc-nc)					
Female	2	0.5	nc	(nc-nc)	Female	9	5.6	160.0	(73.0-303.7)
Lung and Bron	<u>ichus</u>				All Sites / Types				
Male	16	14.7	109.1	(62.3-177.2)	Male	103	101.6	101.4	(82.7-123.0)
Female	15	13.1	114.9	(64.3-189.6)	Female	113	92.5	122.2	(100.7-146.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leicester
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	Obs O	Exp	and Expect	eu case counts, v <u>95% CI</u>	vitti Standardized iricidei	Obs	_	ه SIR	95% CI	
Bladder, Urinar		<u>EXP</u>	SIK	<u>75 /6 CI</u>	Melanoma of Skin		<u>Exp</u>	SIK	93 /0 CI	
Male	<u>y</u> 11	10.2	108.0	(53.9-193.3)	Male	2	5.7	nc	(nc-nc)	
Female	3	3.7	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)	
Brain and Othe				(HC-HC)	Multiple Myeloma	2	4.7	TIC	(110-110)	
Male	1	2.1	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)	
Female	2	1.8	nc	(nc-nc)					(nc-nc)	
Breast	2	1.0	IIC	(110-110)	Female 1 1.2 nc (nc- Non-Hodgkin Lymphoma					
Male	1	0.3	nc	(nc-nc)	Male	5	5.4	92.4	(29.8-215.7)	
Female	45	39.4	114.1	(83.2-152.7)	Female	5	4.9	102.6	(33.0-239.3)	
Cervix Uteri		07.1		(00.2 102.7)	Oral Cavity & Pharynx					
<u> </u>					Male	3	4.0	nc	(nc-nc)	
Female	4	1.8	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)	
Colon / Rectum		1.0	110	(1.0 1.0)	Ovary	•	2.0	110	(110 110)	
Male	<u>.</u> 15	15.5	96.7	(54.1-159.6)	<u>ovary</u>					
Female	13	15.1	86.2	(45.9-147.5)	Female	4	4.2	nc	(nc-nc)	
<u>Esophagus</u>			00.2	(10.7 11.10)	Pancreas Pancreas				()	
Male	3	2.5	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)	
Female	0	0.7	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)	
Hodgkin Lympl		0.7	110	(1.0 1.0)	<u>Prostate</u>	· ·	0.2	110	(110 110)	
Male	0	0.9	nc	(nc-nc)	Male	40	40.6	98.5	(70.4-134.2)	
Female	0	0.8	nc	(nc-nc)	Wale	10	10.0	70.0	(70.1 101.2)	
Kidney & Renal Pelvis					Stomach					
Male	4	4.3	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)	
Female	1	2.8	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)	
<u>Larynx</u>	·	2.0		(1.0 1.0)	<u>Testis</u>	·			()	
Male	4	1.8	nc	(nc-nc)	Male	5	1.6	308.5	(99.4-719.8)	
Female	0	0.5	nc	(nc-nc)					(
<u>Leukemia</u>				()	<u>Thyroid</u>					
Male	4	3.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)	
Female	2	2.7	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)	
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS					
Male	1	2.0	nc nc	(nc-nc)			<u></u>			
Female	0	0.7	nc	(nc-nc)	Female	7	7.9	88.6	(35.5-182.5)	
Lung and Bron	<u>chus</u>			•	All Sites / Types				,	
Male	15	19.3	77.8	(43.5-128.4)	Male	129	137.0	94.2	(78.6-111.9)	
Female	28	17.6	158.9	(105.6-229.7)	Female	134	130.7	102.5	(85.9-121.4)	
									,	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

LenoxObserved and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	Exp	SIR	95% CI	vitri Staridardized iricide	Obs	is, 1999-20 <u>Exp</u>	رن SIR	95% CI
Bladder, Urina		<u>гур</u>	Silk	<u>7370 CI</u>	Melanoma of Skin	003	LVA	<u> </u>	<u>/3/0 CI</u>
Male	17	8.3	204.3	(119.0-327.2)	Male	3	3.9	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	Female	5		156.6	(50.5-365.5)
Brain and Othe				(110 110)	Multiple Myeloma	Ü	0.2	100.0	(00.0 000.0)
Male	2	1.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>	3	1.0	110	(no no)	Non-Hodgkin Lym	(ne ne)			
Male	0	0.2	nc	(nc-nc)	Male	9	3.8	235.5	(107.5-447.1)
Female	26	29.6	87.8	(57.3-128.7)	Female	5		121.5	(39.2-283.7)
Cervix Uteri				(5.15.12017)	Oral Cavity & Pharynx				
					Male	2	2.7	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Colon / Rectun	n			,	Ovary				, ,
Male	- 11	12.3	89.4	(44.6-160.0)					
Female	23	14.6	157.2	(99.6-236.0)	Female	2	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.9	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
Hodgkin Lymp	<u>homa</u>				<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	25	30.8	81.1	(52.5-119.7)
Female	1	0.4	nc	(nc-nc)					
Kidney & Rena	<u>l Pelvis</u>				<u>Stomach</u>				
Male	2	3.0	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	2	2.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	1	1.4	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)	Female	5	6.0	83.3	(26.8-194.3)
Lung and Bronchus					All Sites / Types				
Male	13	15.0	86.9	(46.2-148.6)	Male	108	102.8	105.1	(86.2-126.9)
Female	11	14.9	73.6	(36.7-131.8)	Female	99	106.4	93.0	(75.6-113.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	SIR	95% CI	with Standardized incid	Obs	Exp	SIR	<u>95% CI</u>	
Bladder, Urina	<u>iry</u>				Melanoma of Skin					
Male	39	41.6	93.8	(66.7-128.2)	Male	10	22.6	44.2	(21.1-81.2)	
Female	17	16.0	105.9	(61.7-169.6)	Female	7	19.5	35.9	(14.4-74.0)	
Brain and Other Nervous System					Multiple Myeloma					
Male	8	8.2	97.9	(42.1-192.8)	Male	4	6.0	nc	(nc-nc)	
Female	4	7.5	nc	(nc-nc)	Female	6	5.2	114.6	(41.8-249.5)	
<u>Breast</u>					Non-Hodgkin Lymphoma					
Male	2	1.3	nc	(nc-nc)	Male	27	21.7	124.5	(82.0-181.2)	
Female	133	164.1	81.0	(67.9-96.1)	Female	21	21.0	100.1	(62.0-153.1)	
Cervix Uteri					Oral Cavity & Pha	r <u>ynx</u>				
					Male	16	15.7	101.9	(58.2-165.5)	
Female	7	7.4	94.3	(37.8-194.3)	Female	8	8.3	96.6	(41.6-190.4)	
Colon / Rectur	<u>m</u>				<u>Ovary</u>					
Male	71	63.1	112.6	(87.9-142.0)						
Female	73	66.3	110.1	(86.3-138.4)	Female	19	17.5	108.8	(65.5-169.9)	
Esophagus					<u>Pancreas</u>					
Male	11	10.3	106.8	(53.2-191.0)	Male	16	11.9	134.5	(76.8-218.4)	
Female	2	3.2	nc	(nc-nc)	Female	11	14.0	78.5	(39.1-140.5)	
<u>Hodgkin Lymp</u>	<u>ohoma</u>				<u>Prostate</u>					
Male	6	3.6	168.0	(61.3-365.6)	Male	143	166.4	85.9	(72.4-101.2)	
Female	1	3.2	nc	(nc-nc)						
Kidney & Rena	al Pelvis				<u>Stomach</u>					
Male	17	17.3	98.4	(57.3-157.5)	Male	13	10.6	122.5	(65.2-209.5)	
Female	8	11.7	68.3	(29.4-134.5)	Female	14	7.0	199.3	(108.9-334.4)	
<u>Larynx</u>					<u>Testis</u>					
Male	9	7.2	125.0	(57.0-237.3)	Male	9	6.6	136.9	(62.5-259.9)	
Female	3	2.1	nc	(nc-nc)						
<u>Leukemia</u>					<u>Thyroid</u>					
Male	16	13.4	119.8	(68.4-194.5)	Male	2	4.7	nc	(nc-nc)	
Female	8	11.9	67.4	(29.0-132.8)	Female	12	15.8	75.9	(39.2-132.6)	
Liver and Intrahepatic Bile Ducts					Uteri Corpus and	Uterus, N	<u>10S</u>			
Male	8	8.0	99.8	(43.0-196.7)						
Female	2	3.2	nc	(nc-nc)	Female	27	33.0	81.9	(54.0-119.2)	
Lung and Bron			40	(00 0 1 :)	All Sites / Types			a = =	/aa /	
Male	80	79.2	100.9	(80.0-125.6)	Male	544	557.0	97.7	(89.6-106.2)	
Female	62	76.0	81.6	(62.5-104.6)	Female	471	555.6	84.8	(77.3-92.8)	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;